Hepatitis C, Chronic
Conditions
Brief summary
This multicenter study will evaluate the correlation of interleukin 28B (IL28B) genotypes with disease characteristics and demographics in treatment-naïve and treatment-experienced chronic hepatitis C patients, including patients with HIV co-infection. There will be a single study visit for testing.
Interventions
Blood sampling for ILB28 genotyping
Sponsors
Hoffmann-La Roche
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult (according to local legislation) male or female patient * Chronic hepatitis C (CHC) * Patients naïve to CHC treatment or patients who received prior interferon-based therapy for CHC for whom data on treatment received and treatment outcome is available; information on fibrosis stage prior to previous treatment is also required
Exclusion criteria
* Co-infection with hepatitis B * History or evidence of decompensated liver disease * History of major organ transplantation with an existing functional graft (including liver transplantation) * End stage renal disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | Study Visit 1 (single study visit) | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype (Genotype 1 \[G1\], Genotype 2 \[G2\], Genotype 3 \[G3\], Genotype 4 \[G4\], and all other genotypes \[Other\]) and cirrhosis status ('Cirrhosis/transition to cirrhosis' or 'No cirrhosis') were obtained from medical records. Cirrhosis status was based upon previous biopsy or noninvasive assessment captured prior to treatment, if applicable. |
| Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and cirrhosis status were obtained from medical records. Cirrhosis status was based upon previous biopsy or noninvasive assessment captured prior to treatment, if applicable. |
| Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and cirrhosis status were obtained from medical records. Cirrhosis status was based upon previous biopsy or noninvasive assessment captured prior to treatment, if applicable. |
| Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and cirrhosis status were obtained from medical records. Cirrhosis status was based upon previous biopsy or noninvasive assessment captured prior to treatment, if applicable. |
| Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage ('Cirrhotic,' 'Transition to cirrhosis,' 'Advanced fibrosis noncirrhotic,' 'Mild/minimal fibrosis,' and 'No fibrosis') were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using these five categories and captured prior to treatment, if applicable. |
| Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage ('Cirrhotic,' 'Transition to cirrhosis,' 'Advanced fibrosis noncirrhotic,' 'Mild/minimal fibrosis,' and 'No fibrosis') were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using these five categories and captured prior to treatment, if applicable. |
| Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage ('Cirrhotic,' 'Transition to cirrhosis,' 'Advanced fibrosis noncirrhotic,' 'Mild/minimal fibrosis,' and 'No fibrosis') were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using these five categories and captured prior to treatment, if applicable. |
| Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage ('Cirrhotic,' 'Transition to cirrhosis,' 'Advanced fibrosis noncirrhotic,' 'Mild/minimal fibrosis,' and 'No fibrosis') were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using these five categories and captured prior to treatment, if applicable. |
| Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage (Stage F0, Stage F1, Stage F2, Stage F3, or Stage F4) were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable. |
| Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage (Stage F0, Stage F1, Stage F2, Stage F3, or Stage F4) were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable. |
| Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage (Stage F0, Stage F1, Stage F2, Stage F3, or Stage F4) were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable. |
| Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage (Stage F0, Stage F1, Stage F2, Stage F3, or Stage F4) were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable. |
| Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver elastography (FibroScan) were obtained from medical records. FibroScan values were based upon previous noninvasive assessment captured prior to treatment, if applicable. Mean FibroScan values were determined by averaging the values of all participants within each arm and expressed in kilopascals (kPa). |
| Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver elastography (FibroScan) were obtained from medical records. FibroScan values were based upon previous noninvasive assessment captured prior to treatment, if applicable. Mean FibroScan values were determined by averaging the values of all participants within each arm and expressed in kPa. |
| Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver elastography (FibroScan) were obtained from medical records. FibroScan values were based upon previous noninvasive assessment captured prior to treatment, if applicable. Mean FibroScan values were determined by averaging the values of all participants within each arm and expressed in kPa. |
| Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver elastography (FibroScan) were obtained from medical records. FibroScan values were based upon previous noninvasive assessment captured prior to treatment, if applicable. Mean FibroScan values were determined by averaging the values of all participants within each arm and expressed in kPa. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Body Mass Index (BMI) by IL28B Genotype rs12979860: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including height and pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Each participant's BMI was calculated as weight divided by height-squared, expressed in kilograms per meter-squared (kg/m\^2), and mean BMI was calculated by averaging the values of all participants within each arm. |
| BMI by IL28B Genotype rs12979860: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including height and pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Each participant's BMI was calculated as weight divided by height-squared, expressed in kg/m\^2, and mean BMI was calculated by averaging the values of all participants within each arm. |
| BMI by IL28B Genotype rs8099917: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including height and pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Each participant's BMI was calculated as weight divided by height-squared, expressed in kg/m\^2, and mean BMI was calculated by averaging the values of all participants within each arm. |
| BMI by IL28B Genotype rs8099917: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including height and pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Each participant's BMI was calculated as weight divided by height-squared, expressed in kg/m\^2, and mean BMI was calculated by averaging the values of all participants within each arm. |
| Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records. |
| Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records. |
| Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records. |
| Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records. |
| Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA level was obtained from medical records. Mean HCV RNA level was calculated by averaging the values of all participants within each arm and expressed in log10 international units per milliliter (log10 IU/mL). |
| Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA level was obtained from medical records. Mean HCV RNA level was calculated by averaging the values of all participants within each arm and expressed in log10 IU/mL. |
| Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA level was obtained from medical records. Mean HCV RNA level was calculated by averaging the values of all participants within each arm and expressed in log10 IU/mL. |
| Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA level was obtained from medical records. Mean HCV RNA level was calculated by averaging the values of all participants within each arm and expressed in log10 IU/mL. |
| Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. ALT level was obtained from medical records captured prior to treatment, if applicable. Each participant's ALT ratio was calculated as ALT level divided by the upper limit of normal (55 international units per liter \[IU/L\] for males and 30 IU/L for females). Mean ALT ratio was calculated by averaging the values of all participants within each arm. |
| Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. ALT level was obtained from medical records captured prior to treatment, if applicable. Each participant's ALT ratio was calculated as ALT level divided by the upper limit of normal (55 IU/L for males and 30 IU/L for females). Mean ALT ratio was calculated by averaging the values of all participants within each arm. |
| Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. ALT level was obtained from medical records captured prior to treatment, if applicable. Each participant's ALT ratio was calculated as ALT level divided by the upper limit of normal (55 IU/L for males and 30 IU/L for females). Mean ALT ratio was calculated by averaging the values of all participants within each arm. |
| Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. ALT level was obtained from medical records captured prior to treatment, if applicable. Each participant's ALT ratio was calculated as ALT level divided by the upper limit of normal (55 IU/L for males and 30 IU/L for females). Mean ALT ratio was calculated by averaging the values of all participants within each arm. |
| Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. AST level was obtained from medical records captured prior to treatment, if applicable. Each participant's AST ratio was calculated as AST level divided by the upper limit of normal (40 IU/L for males and 25 IU/L for females). Mean AST ratio was calculated by averaging the values of all participants within each arm. |
| Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. AST level was obtained from medical records captured prior to treatment, if applicable. Each participant's AST ratio was calculated as AST level divided by the upper limit of normal (40 IU/L for males and 25 IU/L for females). Mean AST ratio was calculated by averaging the values of all participants within each arm. |
| Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. AST level was obtained from medical records captured prior to treatment, if applicable. Each participant's AST ratio was calculated as AST level divided by the upper limit of normal (40 IU/L for males and 25 IU/L for females). Mean AST ratio was calculated by averaging the values of all participants within each arm. |
| Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. AST level was obtained from medical records captured prior to treatment, if applicable. Each participant's AST ratio was calculated as AST level divided by the upper limit of normal (40 IU/L for males and 25 IU/L for females). Mean AST ratio was calculated by averaging the values of all participants within each arm. |
| Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Platelet count was obtained from medical records captured prior to treatment, if applicable. Mean platelet count was calculated by averaging the values of all participants within each arm and expressed in 10\^9 cells per liter (10\^9 cells/L). |
| Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Platelet count was obtained from medical records captured prior to treatment, if applicable. Mean platelet count was calculated by averaging the values of all participants within each arm and expressed in 10\^9 cells/L. |
| Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Platelet count was obtained from medical records captured prior to treatment, if applicable. Mean platelet count was calculated by averaging the values of all participants within each arm and expressed in 10\^9 cells/L. |
| Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Platelet count was obtained from medical records captured prior to treatment, if applicable. Mean platelet count was calculated by averaging the values of all participants within each arm and expressed in 10\^9 cells/L. |
| Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment. |
| Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment. |
| Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment. |
| Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment. |
| Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. |
| Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. |
| Number of Participants With Inosine Triphosphatase (ITPA) Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. |
| Number of Participants With ITPA Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. |
| Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment. |
| Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment. |
| Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver inflammation grade (Grade A0, Grade A1, Grade A2, or Grade A3) were obtained from medical records. Liver inflammation grade was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable. |
| Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment. |
| Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment. |
| Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Virological response types within the first 12 weeks of treatment included rapid virological response (RVR), complete early virological response (cEVR), and partial early virological response (pEVR). RVR was defined as an undetectable HCV RNA level within the first 4 weeks, cEVR as an undetectable level within the first 12 weeks, and pEVR as a 2-log drop from Baseline to 12 weeks. Undetectable viral loads include those below the lower limit of detection (LLOD) for the assay performed, which may vary from site to site. Response categories were mutually exclusive, meaning participants could only achieve cEVR/pEVR in the absence of RVR. Participants achieving neither RVR nor cEVR/pEVR were recorded as 'none of the above.' |
| Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Virological response types within the first 12 weeks of treatment included RVR, cEVR, and pEVR. RVR was defined as an undetectable HCV RNA level within the first 4 weeks, cEVR as an undetectable level within the first 12 weeks, and pEVR as a 2-log drop from Baseline to 12 weeks. Undetectable viral loads include those below the LLOD for the assay performed, which may vary from site to site. Response categories were mutually exclusive, meaning participants could only achieve cEVR/pEVR in the absence of RVR. Participants achieving neither RVR nor cEVR/pEVR were recorded as 'none of the above.' |
| Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Virological response types at the end of treatment included undetectable and detectable HCV RNA level. Undetectable viral loads include those below the LLOD for the assay performed, which may vary from site to site. |
| Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Virological response types at the end of treatment included undetectable and detectable HCV RNA level. Undetectable viral loads include those below the LLOD for the assay performed, which may vary from site to site. |
| Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Overall virological response types included sustained virological response (SVR), relapse, and breakthrough. SVR was defined as undetectable HCV RNA level at 24 weeks post-treatment, relapse as an undetectable level at end of treatment with a detectable level at the last post-treatment measurement, and breakthrough as an undetectable level at 1 or more treatment measurements with a detectable level at end of treatment. Undetectable viral loads include those below the LLOD for the assay performed, which may vary from site to site. Response categories were mutually exclusive. Participants with detectable HCV RNA level at 12 or more treatment measurements and who did not meet SVR criteria were considered nonresponders, and those with insufficient treatment response data were recorded as 'none of the above.' |
| Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Overall virological response types included SVR, relapse, and breakthrough. SVR was defined as undetectable HCV RNA level at 24 weeks post-treatment, relapse as an undetectable level at end of treatment with a detectable level at the last post-treatment measurement, and breakthrough as an undetectable level at 1 or more treatment measurements with a detectable level at end of treatment. Undetectable viral loads include those below the LLOD for the assay performed, which may vary from site to site. Response categories were mutually exclusive. Participants with detectable HCV RNA level at 12 or more treatment measurements and who did not meet SVR criteria were considered nonresponders, and those with insufficient treatment response data were recorded as 'none of the above.' |
| Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype and hematology data were obtained from medical records. Participants with a history of a hemoglobin level less than 10 grams per deciliter (g/dL) or a drop of more than 3 g/dL at any time during prior treatment for CHC were recorded as 'yes' for this finding. |
| Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype and hematology data were obtained from medical records. Participants with a history of a hemoglobin level less than 10 g/dL or a drop of more than 3 g/dL at any time during prior treatment for CHC were recorded as 'yes' for this finding. |
| Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records. Past medication use was obtained from medical records and/or participant interview at the Study Visit. Participants with a history of erythropoietin use during prior treatment for CHC were recorded as 'yes' for this finding. |
| Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records. Past medication use was obtained from medical records and/or participant interview at the Study Visit. Participants with a history of erythropoietin use during prior treatment for CHC were recorded as 'yes' for this finding. |
| Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment. |
| Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver inflammation grade (Grade A0, Grade A1, Grade A2, or Grade A3) were obtained from medical records. Liver inflammation grade was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable. |
| Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver inflammation grade (Grade A0, Grade A1, Grade A2, or Grade A3) were obtained from medical records. Liver inflammation grade was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable. |
| Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver inflammation grade (Grade A0, Grade A1, Grade A2, or Grade A3) were obtained from medical records. Liver inflammation grade was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable. |
| Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including gender, were obtained from medical records and/or participant interview at the Study Visit. |
| Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including gender, were obtained from medical records and/or participant interview at the Study Visit. |
| Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including gender, were obtained from medical records and/or participant interview at the Study Visit. |
| Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including gender, were obtained from medical records and/or participant interview at the Study Visit. |
| Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including self-reported ethnic origin, were obtained from medical records and/or participant interview at the Study Visit. |
| Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including self-reported ethnic origin, were obtained from medical records and/or participant interview at the Study Visit. |
| Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including self-reported ethnic origin, were obtained from medical records and/or participant interview at the Study Visit. |
| Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including self-reported ethnic origin, were obtained from medical records and/or participant interview at the Study Visit. |
| Mean Body Weight by IL28B Genotype rs12979860: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Mean body weight was calculated by averaging the values of all participants within each arm and expressed in kilograms (kg). |
| Mean Body Weight by IL28B Genotype rs12979860: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Mean body weight was calculated by averaging the values of all participants within each arm and expressed in kg. |
| Mean Body Weight by IL28B Genotype rs8099917: Treatment-Naive | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Mean body weight was calculated by averaging the values of all participants within each arm and expressed in kg. |
| Mean Body Weight by IL28B Genotype rs8099917: Treatment-Experienced | Study Visit 1 | Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Mean body weight was calculated by averaging the values of all participants within each arm and expressed in kg. |
Countries
Argentina, Belgium, Chile, Egypt, Estonia, France, Germany, Greece, Italy, Kuwait, Latvia, Lebanon, Lithuania, Mexico, North Macedonia, Oman, Pakistan, Peru, Portugal, Qatar, Romania, Serbia, Slovakia, Sweden, Switzerland, Syria, Taiwan, Turkey (Türkiye), United Arab Emirates, United States, Venezuela
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Participants With CHC Both treatment-naive and treatment-experienced participants with CHC were enrolled in this prospective, interventional Phase 4 study. | 4,616 |
| Total | 4,616 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Lost to Follow-up | 5 |
| Overall Study | Other | 2 |
| Overall Study | Participant Refused Sample Collection | 18 |
| Overall Study | Sample not Collected by Mistake | 2 |
| Overall Study | Withdrawal by Subject | 7 |
Baseline characteristics
| Characteristic | Participants With CHC |
|---|---|
| Age, Continuous | 49.1 years STANDARD_DEVIATION 12.87 |
| Sex: Female, Male Female | 2043 Participants |
| Sex: Female, Male Male | 2573 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 4,733 |
Outcome results
Primary
Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver elastography (FibroScan) were obtained from medical records. FibroScan values were based upon previous noninvasive assessment captured prior to treatment, if applicable. Mean FibroScan values were determined by averaging the values of all participants within each arm and expressed in kPa.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G1 (n=27,84,32) | 11.7 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G2 (n=6,10,0) | 13.3 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G3 (n=15,14,4) | 12.3 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G4 (n=6,14,3) | 10.7 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Other (n=0,0,0) | NA kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Total (n=54,122,39) | 11.9 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Total (n=54,122,39) | 11.7 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G1 (n=27,84,32) | 13.2 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G4 (n=6,14,3) | 10.6 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Other (n=0,0,0) | NA kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G2 (n=6,10,0) | 5.11 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G3 (n=15,14,4) | 8.64 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G2 (n=6,10,0) | 8.17 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G3 (n=15,14,4) | 9.48 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Total (n=54,122,39) | 12.8 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G4 (n=6,14,3) | 8.9 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G1 (n=27,84,32) | 13.5 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Other (n=0,0,0) | NA kPa |
Comparison: G1p-value: 0.7454Jonckheere-Terpstra Test
Comparison: G2p-value: 0.0016Jonckheere-Terpstra Test
Comparison: G3p-value: 0.5261Jonckheere-Terpstra Test
Comparison: G4p-value: 0.3422Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.9026Jonckheere-Terpstra Test
Primary
Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver elastography (FibroScan) were obtained from medical records. FibroScan values were based upon previous noninvasive assessment captured prior to treatment, if applicable. Mean FibroScan values were determined by averaging the values of all participants within each arm and expressed in kilopascals (kPa).
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G3 (n=60,83,24) | 11.7 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G1 (n=177,316,82) | 9.61 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G4 (n=43,59,18) | 11.4 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Total (n=324,517,140) | 10.5 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G2 (n=40,55,15) | 11.1 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Other (n=4,4,1) | 12.1 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G2 (n=40,55,15) | 7.69 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G1 (n=177,316,82) | 10.2 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G3 (n=60,83,24) | 9.3 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G4 (n=43,59,18) | 13.4 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Other (n=4,4,1) | 21.9 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Total (n=324,517,140) | 10.2 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G2 (n=40,55,15) | 7.15 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Total (n=324,517,140) | 11.2 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Other (n=4,4,1) | 4.00 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G3 (n=60,83,24) | 8.99 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G1 (n=177,316,82) | 12.6 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G4 (n=43,59,18) | 11.1 kPa |
Comparison: Total genotypesp-value: 0.9159Jonckheere-Terpstra Test
Comparison: G1p-value: 0.0605Jonckheere-Terpstra Test
Comparison: G2p-value: 0.0899Jonckheere-Terpstra Test
Comparison: G3p-value: 0.0634Jonckheere-Terpstra Test
Comparison: G4p-value: 0.6165Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.1649Jonckheere-Terpstra Test
Primary
Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver elastography (FibroScan) were obtained from medical records. FibroScan values were based upon previous noninvasive assessment captured prior to treatment, if applicable. Mean FibroScan values were determined by averaging the values of all participants within each arm and expressed in kPa.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G1 (n=53,77,13) | 12.7 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G2 (n=9,7,0) | 10.5 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G3 (n=21,10,2) | 12.1 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G4 (n=14,9,0) | 9.74 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Other (n=0,0,0) | NA kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Total (n=97,103,15) | 11.9 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Total (n=97,103,15) | 12.4 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G1 (n=53,77,13) | 13.7 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G4 (n=14,9,0) | 11.4 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Other (n=0,0,0) | NA kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G2 (n=9,7,0) | 5.21 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G3 (n=21,10,2) | 7.82 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G2 (n=9,7,0) | NA kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G3 (n=21,10,2) | 5.95 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Total (n=97,103,15) | 9.62 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G4 (n=14,9,0) | NA kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G1 (n=53,77,13) | 10.2 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Other (n=0,0,0) | NA kPa |
Comparison: G1p-value: 0.4207Jonckheere-Terpstra Test
Comparison: G2p-value: 0.0566Jonckheere-Terpstra Test
Comparison: G3p-value: 0.1211Jonckheere-Terpstra Test
Comparison: G4p-value: 0.3772Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.4023Jonckheere-Terpstra Test
Primary
Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver elastography (FibroScan) were obtained from medical records. FibroScan values were based upon previous noninvasive assessment captured prior to treatment, if applicable. Mean FibroScan values were determined by averaging the values of all participants within each arm and expressed in kPa.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G1 (n=287,259,29) | 9.46 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G2 (n=63,42,5) | 9.44 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G3 (n=100,57,10) | 11.4 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G4 (n=72,44,4) | 11.2 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Other (n=6,2,1) | 9.32 kPa |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Total (n=528,404,49) | 10.1 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Total (n=528,404,49) | 10.8 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G1 (n=287,259,29) | 10.9 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G4 (n=72,44,4) | 14.2 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Other (n=6,2,1) | 40.1 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G2 (n=63,42,5) | 7.95 kPa |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G3 (n=100,57,10) | 8.45 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G2 (n=63,42,5) | 8.76 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G3 (n=100,57,10) | 6.51 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Total (n=528,404,49) | 11.5 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G4 (n=72,44,4) | 13.7 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G1 (n=287,259,29) | 13.7 kPa |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean FibroScan Values by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Other (n=6,2,1) | 4.00 kPa |
Comparison: G1p-value: 0.0017Jonckheere-Terpstra Test
Comparison: G2p-value: 0.8864Jonckheere-Terpstra Test
Comparison: G3p-value: 0.0291Jonckheere-Terpstra Test
Comparison: G4p-value: 0.5472Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 1Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.1148Jonckheere-Terpstra Test
Primary
Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and cirrhosis status were obtained from medical records. Cirrhosis status was based upon previous biopsy or noninvasive assessment captured prior to treatment, if applicable.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced): Only participants who had received prior treatment for CHC were included in the analysis; n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G1, Cirrhosis (n=281,653,226) | 93 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G1, No cirrhosis (n=281,653,226) | 188 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G2, Cirrhosis (n=89,36,9) | 30 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G2, No cirrhosis (n=89,36,9) | 59 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G3, Cirrhosis (n=55,75,19) | 19 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G3, No cirrhosis (n=55,75,19) | 36 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G4, Cirrhosis (n=25,66,19) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G4, No cirrhosis (n=25,66,19) | 21 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Other, Cirrhosis (n=12,20,2) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Other, No cirrhosis (n=12,20,2) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Total, Cirrhosis (n=462,850,275) | 152 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Total, No cirrhosis (n=462,850,275) | 310 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Total, No cirrhosis (n=462,850,275) | 586 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G1, Cirrhosis (n=281,653,226) | 208 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G4, Cirrhosis (n=25,66,19) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Other, Cirrhosis (n=12,20,2) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G1, No cirrhosis (n=281,653,226) | 445 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G3, No cirrhosis (n=55,75,19) | 49 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Total, Cirrhosis (n=462,850,275) | 264 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G2, Cirrhosis (n=89,36,9) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G4, No cirrhosis (n=25,66,19) | 51 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G3, Cirrhosis (n=55,75,19) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G2, No cirrhosis (n=89,36,9) | 28 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Other, No cirrhosis (n=12,20,2) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G2, No cirrhosis (n=89,36,9) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G3, Cirrhosis (n=55,75,19) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Other, No cirrhosis (n=12,20,2) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G3, No cirrhosis (n=55,75,19) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G4, Cirrhosis (n=25,66,19) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G4, No cirrhosis (n=25,66,19) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Total, Cirrhosis (n=462,850,275) | 81 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G1, Cirrhosis (n=281,653,226) | 67 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G1, No cirrhosis (n=281,653,226) | 159 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Other, Cirrhosis (n=12,20,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G2, Cirrhosis (n=89,36,9) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Total, No cirrhosis (n=462,850,275) | 194 participants |
Comparison: G4p-value: 0.3975Cochran-Armitage Trend Test
Comparison: Other genotypesp-value: 0.1781Cochran-Armitage Trend Test
Comparison: Total genotypesp-value: 0.3159Cochran-Armitage Trend Test
Comparison: G1p-value: 0.4133Cochran-Armitage Trend Test
Comparison: G2p-value: 0.44Cochran-Armitage Trend Test
Comparison: G3p-value: 0.8597Cochran-Armitage Trend Test
Primary
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage ('Cirrhotic,' 'Transition to cirrhosis,' 'Advanced fibrosis noncirrhotic,' 'Mild/minimal fibrosis,' and 'No fibrosis') were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using these five categories and captured prior to treatment, if applicable.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Cirrhotic (n=26,31,7) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Transition (n=277,511,164) | 51 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Cirrhotic (n=7,12,1) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Transition (n=26,31,7) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, No fibrosis (n=186,422,141) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, No fibrosis (n=9,35,10) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Advanced (n=26,31,7) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Mild (n=277,511,164) | 84 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Mild (n=9,35,10) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Mild (n=26,31,7) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Cirrhotic (n=277,511,164) | 32 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Advanced (n=9,35,10) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, No fibrosis (n=26,31,7) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Cirrhotic (n=49,11,5) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Transition (n=9,35,10) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Cirrhotic (n=9,35,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Advanced (n=186,422,141) | 63 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, No fibrosis (n=7,12,1) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Transition (n=49,11,5) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Transition (n=186,422,141) | 35 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Mild (n=7,12,1) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Advanced (n=49,11,5) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Advanced (n=277,511,164) | 88 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Cirrhotic (n=186,422,141) | 20 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Mild (n=49,11,5) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Mild (n=186,422,141) | 55 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Advanced (n=7,12,1) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, No fibrosis (n=49,11,5) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, No fibrosis (n=277,511,164) | 22 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Transition (n=7,12,1) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Advanced (n=7,12,1) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Cirrhotic (n=186,422,141) | 41 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Transition (n=186,422,141) | 86 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Advanced (n=186,422,141) | 111 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Mild (n=186,422,141) | 141 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, No fibrosis (n=186,422,141) | 43 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Cirrhotic (n=49,11,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Transition (n=49,11,5) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Advanced (n=49,11,5) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Mild (n=49,11,5) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, No fibrosis (n=49,11,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Cirrhotic (n=26,31,7) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Transition (n=26,31,7) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Advanced (n=26,31,7) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Mild (n=26,31,7) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, No fibrosis (n=26,31,7) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Cirrhotic (n=9,35,10) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Transition (n=9,35,10) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Advanced (n=9,35,10) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Mild (n=9,35,10) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, No fibrosis (n=9,35,10) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Cirrhotic (n=7,12,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Transition (n=7,12,1) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Mild (n=7,12,1) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, No fibrosis (n=7,12,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Cirrhotic (n=277,511,164) | 54 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Transition (n=277,511,164) | 96 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Advanced (n=277,511,164) | 140 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Mild (n=277,511,164) | 173 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, No fibrosis (n=277,511,164) | 48 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Cirrhotic (n=26,31,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Advanced (n=186,422,141) | 40 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Cirrhotic (n=7,12,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, No fibrosis (n=49,11,5) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Cirrhotic (n=186,422,141) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Transition (n=7,12,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Mild (n=49,11,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Advanced (n=49,11,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Advanced (n=7,12,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Transition (n=49,11,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Advanced (n=277,511,164) | 47 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Mild (n=7,12,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Cirrhotic (n=49,11,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Transition (n=186,422,141) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, No fibrosis (n=7,12,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, No fibrosis (n=186,422,141) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, No fibrosis (n=277,511,164) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Cirrhotic (n=9,35,10) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, No fibrosis (n=26,31,7) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Cirrhotic (n=277,511,164) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Transition (n=9,35,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Mild (n=26,31,7) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Mild (n=186,422,141) | 50 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Advanced (n=9,35,10) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Advanced (n=26,31,7) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Mild (n=277,511,164) | 57 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Mild (n=9,35,10) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Transition (n=26,31,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Transition (n=277,511,164) | 28 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, No fibrosis (n=9,35,10) | 1 participants |
Comparison: G1p-value: 0.0911Jonckheere-Terpstra Test
Comparison: G2p-value: 0.4674Jonckheere-Terpstra Test
Comparison: G3p-value: 0.1604Jonckheere-Terpstra Test
Comparison: G4p-value: 0.5937Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.383Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.0507Jonckheere-Terpstra Test
Primary
Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage ('Cirrhotic,' 'Transition to cirrhosis,' 'Advanced fibrosis noncirrhotic,' 'Mild/minimal fibrosis,' and 'No fibrosis') were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using these five categories and captured prior to treatment, if applicable.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Advanced (n=331,465,126) | 81 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Advanced (n=28,48,12) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Mild (n=24,25,5) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Transition (n=331,465,126) | 48 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Mild (n=28,48,12) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Mild (n=207,324,91) | 101 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Cirrhotic (n=331,465,126) | 21 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, No fibrosis (n=28,48,12) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Transition (n=67,65,16) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, No fibrosis (n=5,3,2) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Cirrhotic (n=5,3,2) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Advanced (n=24,25,5) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Mild (n=5,3,2) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Transition (n=5,3,2) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Advanced (n=207,324,91) | 51 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Advanced (n=5,3,2) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Advanced (n=67,65,16) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Cirrhotic (n=24,25,5) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Transition (n=207,324,91) | 28 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Mild (n=67,65,16) | 28 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, No fibrosis (n=24,25,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Cirrhotic (n=207,324,91) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, No fibrosis (n=67,65,16) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Transition (n=24,25,5) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, No fibrosis (n=331,465,126) | 26 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Cirrhotic (n=28,48,12) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, No fibrosis (n=207,324,91) | 17 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Mild (n=331,465,126) | 155 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Transition (n=28,48,12) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Cirrhotic (n=67,65,16) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Transition (n=24,25,5) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Advanced (n=24,25,5) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Mild (n=24,25,5) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, No fibrosis (n=24,25,5) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Cirrhotic (n=67,65,16) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Transition (n=67,65,16) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Advanced (n=67,65,16) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Mild (n=67,65,16) | 32 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, No fibrosis (n=67,65,16) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Cirrhotic (n=28,48,12) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Transition (n=28,48,12) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Advanced (n=28,48,12) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Mild (n=28,48,12) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, No fibrosis (n=28,48,12) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Cirrhotic (n=5,3,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Transition (n=5,3,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Advanced (n=5,3,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Mild (n=5,3,2) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, No fibrosis (n=5,3,2) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Cirrhotic (n=331,465,126) | 25 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Transition (n=331,465,126) | 52 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Advanced (n=331,465,126) | 119 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Mild (n=331,465,126) | 208 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, No fibrosis (n=331,465,126) | 61 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Cirrhotic (n=207,324,91) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Transition (n=207,324,91) | 40 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Advanced (n=207,324,91) | 88 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Mild (n=207,324,91) | 140 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, No fibrosis (n=207,324,91) | 39 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Cirrhotic (n=24,25,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Transition (n=331,465,126) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Transition (n=28,48,12) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Mild (n=207,324,91) | 34 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Advanced (n=331,465,126) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Cirrhotic (n=28,48,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, No fibrosis (n=24,25,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Mild (n=331,465,126) | 51 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, No fibrosis (n=67,65,16) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Advanced (n=24,25,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, No fibrosis (n=331,465,126) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Mild (n=67,65,16) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, No fibrosis (n=207,324,91) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Cirrhotic (n=207,324,91) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Advanced (n=67,65,16) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Mild (n=24,25,5) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Transition (n=207,324,91) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Transition (n=5,3,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Transition (n=67,65,16) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Advanced (n=5,3,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Cirrhotic (n=5,3,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Transition (n=24,25,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Mild (n=5,3,2) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, No fibrosis (n=28,48,12) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Advanced (n=207,324,91) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, No fibrosis (n=5,3,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Mild (n=28,48,12) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Cirrhotic (n=67,65,16) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Cirrhotic (n=331,465,126) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Advanced (n=28,48,12) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Cirrhotic (n=24,25,5) | 0 participants |
Comparison: G1p-value: 0.1981Jonckheere-Terpstra Test
Comparison: G2p-value: 0.1616Jonckheere-Terpstra Test
Comparison: G3p-value: 0.1192Jonckheere-Terpstra Test
Comparison: G4p-value: 0.4485Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.1525Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.7262Jonckheere-Terpstra Test
Primary
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage (Stage F0, Stage F1, Stage F2, Stage F3, or Stage F4) were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F0 (n=16,23,5) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F1 (n=174,322,86) | 44 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F0 (n=3,3,1) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F1 (n=16,23,5) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F4 (n=119,259,70) | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F4 (n=5,30,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F2 (n=16,23,5) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F3 (n=174,322,86) | 36 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F3 (n=5,30,9) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F3 (n=16,23,5) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F0 (n=174,322,86) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F2 (n=5,30,9) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F4 (n=16,23,5) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F0 (n=31,7,1) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F1 (n=5,30,9) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F0 (n=5,30,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F2 (n=119,259,70) | 44 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F4 (n=3,3,1) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F1 (n=31,7,1) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F1 (n=119,259,70) | 28 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F3 (n=3,3,1) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F2 (n=31,7,1) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F2 (n=174,322,86) | 61 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F0 (n=119,259,70) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F3 (n=31,7,1) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F3 (n=119,259,70) | 26 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F2 (n=3,3,1) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F4 (n=31,7,1) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F4 (n=174,322,86) | 24 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F1 (n=3,3,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F2 (n=3,3,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F0 (n=119,259,70) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F1 (n=119,259,70) | 61 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F2 (n=119,259,70) | 83 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F3 (n=119,259,70) | 62 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F4 (n=119,259,70) | 33 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F0 (n=31,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F1 (n=31,7,1) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F2 (n=31,7,1) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F3 (n=31,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F4 (n=31,7,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F0 (n=16,23,5) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F1 (n=16,23,5) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F2 (n=16,23,5) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F3 (n=16,23,5) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F4 (n=16,23,5) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F0 (n=5,30,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F1 (n=5,30,9) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F2 (n=5,30,9) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F3 (n=5,30,9) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F4 (n=5,30,9) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F0 (n=3,3,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F1 (n=3,3,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F3 (n=3,3,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F4 (n=3,3,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F0 (n=174,322,86) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F1 (n=174,322,86) | 80 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F2 (n=174,322,86) | 108 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F3 (n=174,322,86) | 67 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F4 (n=174,322,86) | 44 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F0 (n=16,23,5) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F2 (n=119,259,70) | 31 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F0 (n=3,3,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F4 (n=31,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F0 (n=119,259,70) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F1 (n=3,3,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F3 (n=31,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F2 (n=31,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F2 (n=3,3,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F1 (n=31,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F2 (n=174,322,86) | 37 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F3 (n=3,3,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F0 (n=31,7,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F1 (n=119,259,70) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F4 (n=3,3,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F4 (n=119,259,70) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F4 (n=174,322,86) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F0 (n=5,30,9) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F4 (n=16,23,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F0 (n=174,322,86) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F1 (n=5,30,9) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F3 (n=16,23,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F3 (n=119,259,70) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F2 (n=5,30,9) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F2 (n=16,23,5) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F3 (n=174,322,86) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F3 (n=5,30,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F1 (n=16,23,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F1 (n=174,322,86) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F4 (n=5,30,9) | 2 participants |
Comparison: G1p-value: 0.251Jonckheere-Terpstra Test
Comparison: G2p-value: 0.2943Jonckheere-Terpstra Test
Comparison: G3p-value: 0.0478Jonckheere-Terpstra Test
Comparison: G4p-value: 0.5387Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.3878Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.0748Jonckheere-Terpstra Test
Primary
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage (Stage F0, Stage F1, Stage F2, Stage F3, or Stage F4) were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F0 (n=31,26,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F1 (n=166,249,77) | 59 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F0 (n=4,0,2) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F1 (n=31,26,9) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F4 (n=95,177,56) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F4 (n=21,35,8) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F2 (n=31,26,9) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F3 (n=166,249,77) | 29 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F3 (n=21,35,8) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F3 (n=31,26,9) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F0 (n=166,249,77) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F2 (n=21,35,8) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F4 (n=31,26,9) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F0 (n=15,11,2) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F1 (n=21,35,8) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F0 (n=21,35,8) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F2 (n=95,177,56) | 34 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F4 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F1 (n=15,11,2) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F1 (n=95,177,56) | 33 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F3 (n=4,0,2) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F2 (n=15,11,2) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F2 (n=166,249,77) | 55 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F0 (n=95,177,56) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F3 (n=15,11,2) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F3 (n=95,177,56) | 16 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F2 (n=4,0,2) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F4 (n=15,11,2) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F4 (n=166,249,77) | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F1 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F2 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F0 (n=95,177,56) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F1 (n=95,177,56) | 63 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F2 (n=95,177,56) | 57 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F3 (n=95,177,56) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F4 (n=95,177,56) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F0 (n=15,11,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F1 (n=15,11,2) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F2 (n=15,11,2) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F3 (n=15,11,2) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F4 (n=15,11,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F0 (n=31,26,9) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F1 (n=31,26,9) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F2 (n=31,26,9) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F3 (n=31,26,9) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F4 (n=31,26,9) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F0 (n=21,35,8) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F1 (n=21,35,8) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F2 (n=21,35,8) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F3 (n=21,35,8) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F4 (n=21,35,8) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F0 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F1 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F3 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F4 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F0 (n=166,249,77) | 29 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F1 (n=166,249,77) | 90 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F2 (n=166,249,77) | 79 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F3 (n=166,249,77) | 32 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F4 (n=166,249,77) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F0 (n=31,26,9) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F2 (n=95,177,56) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F0 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F4 (n=15,11,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F0 (n=95,177,56) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F1 (n=4,0,2) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F3 (n=15,11,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F2 (n=15,11,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F2 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F1 (n=15,11,2) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F2 (n=166,249,77) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F3 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F0 (n=15,11,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F1 (n=95,177,56) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F4 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F4 (n=95,177,56) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F4 (n=166,249,77) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F0 (n=21,35,8) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F4 (n=31,26,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F0 (n=166,249,77) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F1 (n=21,35,8) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F3 (n=31,26,9) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F3 (n=95,177,56) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F2 (n=21,35,8) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F2 (n=31,26,9) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F3 (n=166,249,77) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F3 (n=21,35,8) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F1 (n=31,26,9) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F1 (n=166,249,77) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F4 (n=21,35,8) | 0 participants |
Comparison: G1p-value: 0.5348Jonckheere-Terpstra Test
Comparison: G2p-value: 0.5469Jonckheere-Terpstra Test
Comparison: G3p-value: 0.0463Jonckheere-Terpstra Test
Comparison: G4p-value: 0.9393Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.3404Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.4237Jonckheere-Terpstra Test
Primary
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and cirrhosis status were obtained from medical records. Cirrhosis status was based upon previous biopsy or noninvasive assessment captured prior to treatment, if applicable.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G1, Cirrhosis (n=528,539,93) | 158 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G1, No cirrhosis (n=528,539,93) | 370 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G2, Cirrhosis (n=102,25,7) | 35 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G2, No cirrhosis (n=102,25,7) | 67 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G3, Cirrhosis (n=81,59,9) | 29 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G3, No cirrhosis (n=81,59,9) | 52 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G4, Cirrhosis (n=70,40,0) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G4, No cirrhosis (n=70,40,0) | 59 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Other, Cirrhosis (n=15,19,0) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Other, No cirrhosis (n=15,19,0) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Total, Cirrhosis (n=796,682,109) | 241 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Total, No cirrhosis (n=796,682,109) | 555 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Total, No cirrhosis (n=796,682,109) | 463 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G1, Cirrhosis (n=528,539,93) | 179 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G4, Cirrhosis (n=70,40,0) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Other, Cirrhosis (n=15,19,0) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G1, No cirrhosis (n=528,539,93) | 360 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G3, No cirrhosis (n=81,59,9) | 40 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Total, Cirrhosis (n=796,682,109) | 219 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G2, Cirrhosis (n=102,25,7) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G4, No cirrhosis (n=70,40,0) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G3, Cirrhosis (n=81,59,9) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G2, No cirrhosis (n=102,25,7) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Other, No cirrhosis (n=15,19,0) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G2, No cirrhosis (n=102,25,7) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G3, Cirrhosis (n=81,59,9) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Other, No cirrhosis (n=15,19,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G3, No cirrhosis (n=81,59,9) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G4, Cirrhosis (n=70,40,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G4, No cirrhosis (n=70,40,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Total, Cirrhosis (n=796,682,109) | 37 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G1, Cirrhosis (n=528,539,93) | 31 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G1, No cirrhosis (n=528,539,93) | 62 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Other, Cirrhosis (n=15,19,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | G2, Cirrhosis (n=102,25,7) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced | Total, No cirrhosis (n=796,682,109) | 72 participants |
Comparison: G1p-value: 0.2693Cochran-Armitage Trend Test
Comparison: G2p-value: 0.324Cochran-Armitage Trend Test
Comparison: G3p-value: 0.7006Cochran-Armitage Trend Test
Comparison: G4p-value: 0.0403Cochran-Armitage Trend Test
Comparison: Other genotypesp-value: 0.1075Cochran-Armitage Trend Test
Comparison: Total genotypesp-value: 0.3295Cochran-Armitage Trend Test
Primary
Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and cirrhosis status were obtained from medical records. Cirrhosis status was based upon previous biopsy or noninvasive assessment captured prior to treatment, if applicable.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G1, Cirrhosis (n=835,745,116) | 200 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G1, No cirrhosis (n=835,745,116) | 635 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G2, Cirrhosis (n=197,111,12) | 33 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G2, No cirrhosis (n=197,111,12) | 164 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G3, Cirrhosis (n=360,185,27) | 111 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G3, No cirrhosis (n=360,185,27) | 249 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G4, Cirrhosis (n=164,85,10) | 45 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G4, No cirrhosis (n=164,85,10) | 119 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | Other, Cirrhosis (n=37,15,3) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | Other, No cirrhosis (n=37,15,3) | 26 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | Total, Cirrhosis (n=1593,1141,168) | 400 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | Total, No cirrhosis (n=1593,1141,168) | 1193 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | Total, No cirrhosis (n=1593,1141,168) | 832 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G1, Cirrhosis (n=835,745,116) | 217 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G4, Cirrhosis (n=164,85,10) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | Other, Cirrhosis (n=37,15,3) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G1, No cirrhosis (n=835,745,116) | 528 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G3, No cirrhosis (n=360,185,27) | 143 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | Total, Cirrhosis (n=1593,1141,168) | 309 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G2, Cirrhosis (n=197,111,12) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G4, No cirrhosis (n=164,85,10) | 59 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G3, Cirrhosis (n=360,185,27) | 42 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G2, No cirrhosis (n=197,111,12) | 92 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | Other, No cirrhosis (n=37,15,3) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G2, No cirrhosis (n=197,111,12) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G3, Cirrhosis (n=360,185,27) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | Other, No cirrhosis (n=37,15,3) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G3, No cirrhosis (n=360,185,27) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G4, Cirrhosis (n=164,85,10) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G4, No cirrhosis (n=164,85,10) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | Total, Cirrhosis (n=1593,1141,168) | 48 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G1, Cirrhosis (n=835,745,116) | 36 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G1, No cirrhosis (n=835,745,116) | 80 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | Other, Cirrhosis (n=37,15,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | G2, Cirrhosis (n=197,111,12) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive | Total, No cirrhosis (n=1593,1141,168) | 120 participants |
Comparison: G1p-value: 0.0126Cochran-Armitage Trend Test
Comparison: G2p-value: 0.7174Cochran-Armitage Trend Test
Comparison: G3p-value: 0.138Cochran-Armitage Trend Test
Comparison: G4p-value: 0.6258Cochran-Armitage Trend Test
Comparison: Other genotypesp-value: 0.5751Cochran-Armitage Trend Test
Comparison: Total genotypesp-value: 0.1681Cochran-Armitage Trend Test
Primary
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage ('Cirrhotic,' 'Transition to cirrhosis,' 'Advanced fibrosis noncirrhotic,' 'Mild/minimal fibrosis,' and 'No fibrosis') were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using these five categories and captured prior to treatment, if applicable.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Cirrhotic (n=38,22,4) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Transition (n=468,415,69) | 78 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Cirrhotic (n=9,11,0) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Transition (n=38,22,4) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, No fibrosis (n=332,356,61) | 25 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, No fibrosis (n=37,17,0) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Advanced (n=38,22,4) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Cirrhotic (n=468,415,69) | 52 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Mild (n=37,17,0) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Mild (n=38,22,4) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Mild (n=468,415,69) | 147 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Advanced (n=37,17,0) | 18 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, No fibrosis (n=38,22,4) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, No fibrosis (n=9,11,0) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Transition (n=37,17,0) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Cirrhotic (n=37,17,0) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Cirrhotic (n=52,9,4) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Advanced (n=332,356,61) | 109 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Mild (n=9,11,0) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Transition (n=52,9,4) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Transition (n=332,356,61) | 58 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Advanced (n=52,9,4) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Advanced (n=468,415,69) | 152 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Cirrhotic (n=332,356,61) | 34 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Mild (n=52,9,4) | 16 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Mild (n=332,356,61) | 106 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Advanced (n=9,11,0) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, No fibrosis (n=52,9,4) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, No fibrosis (n=468,415,69) | 39 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Transition (n=9,11,0) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Advanced (n=9,11,0) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Cirrhotic (n=332,356,61) | 32 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Transition (n=332,356,61) | 74 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Advanced (n=332,356,61) | 92 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Mild (n=332,356,61) | 119 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, No fibrosis (n=332,356,61) | 39 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Cirrhotic (n=52,9,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Transition (n=52,9,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Advanced (n=52,9,4) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Mild (n=52,9,4) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, No fibrosis (n=52,9,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Cirrhotic (n=38,22,4) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Transition (n=38,22,4) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Advanced (n=38,22,4) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Mild (n=38,22,4) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, No fibrosis (n=38,22,4) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Cirrhotic (n=37,17,0) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Transition (n=37,17,0) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Advanced (n=37,17,0) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Mild (n=37,17,0) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, No fibrosis (n=37,17,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Cirrhotic (n=9,11,0) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Transition (n=9,11,0) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Mild (n=9,11,0) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, No fibrosis (n=9,11,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Cirrhotic (n=468,415,69) | 41 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Transition (n=468,415,69) | 80 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Advanced (n=468,415,69) | 108 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Mild (n=468,415,69) | 145 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, No fibrosis (n=468,415,69) | 41 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Cirrhotic (n=38,22,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Advanced (n=332,356,61) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Cirrhotic (n=9,11,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, No fibrosis (n=52,9,4) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Cirrhotic (n=332,356,61) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Transition (n=9,11,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Mild (n=52,9,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Advanced (n=52,9,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Advanced (n=9,11,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Cirrhotic (n=52,9,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Advanced (n=468,415,69) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Mild (n=9,11,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, No fibrosis (n=332,356,61) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Transition (n=332,356,61) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, No fibrosis (n=9,11,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Transition (n=52,9,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, No fibrosis (n=468,415,69) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Cirrhotic (n=37,17,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, No fibrosis (n=38,22,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Cirrhotic (n=468,415,69) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Transition (n=37,17,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Mild (n=38,22,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Mild (n=332,356,61) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Advanced (n=37,17,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Advanced (n=38,22,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Mild (n=468,415,69) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Mild (n=37,17,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Transition (n=38,22,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Transition (n=468,415,69) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, No fibrosis (n=37,17,0) | 0 participants |
Comparison: G1p-value: 0.3709Jonckheere-Terpstra Test
Comparison: G2p-value: 0.2054Jonckheere-Terpstra Test
Comparison: G3p-value: 0.8457Jonckheere-Terpstra Test
Comparison: G4p-value: 0.3492Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.2846Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.2646Jonckheere-Terpstra Test
Primary
Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage ('Cirrhotic,' 'Transition to cirrhosis,' 'Advanced fibrosis noncirrhotic,' 'Mild/minimal fibrosis,' and 'No fibrosis') were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using these five categories and captured prior to treatment, if applicable.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Cirrhotic (n=98,42,8) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Transition (n=527,343,52) | 70 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Cirrhotic (n=6,3,1) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Transition (n=98,42,8) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, No fibrosis (n=331,252,39) | 33 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, No fibrosis (n=59,27,2) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Advanced (n=98,42,8) | 18 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Mild (n=527,343,52) | 235 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Mild (n=59,27,2) | 32 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Mild (n=98,42,8) | 40 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Cirrhotic (n=527,343,52) | 37 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Advanced (n=59,27,2) | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, No fibrosis (n=98,42,8) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Cirrhotic (n=33,19,2) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Transition (n=59,27,2) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Cirrhotic (n=59,27,2) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Advanced (n=331,252,39) | 89 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, No fibrosis (n=6,3,1) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Transition (n=33,19,2) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Transition (n=331,252,39) | 44 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Mild (n=6,3,1) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Advanced (n=33,19,2) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Advanced (n=527,343,52) | 133 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Cirrhotic (n=331,252,39) | 20 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Mild (n=33,19,2) | 17 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Mild (n=331,252,39) | 145 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Advanced (n=6,3,1) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, No fibrosis (n=33,19,2) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, No fibrosis (n=527,343,52) | 52 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Transition (n=6,3,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Advanced (n=6,3,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Cirrhotic (n=331,252,39) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Transition (n=331,252,39) | 34 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Advanced (n=331,252,39) | 62 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Mild (n=331,252,39) | 110 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, No fibrosis (n=331,252,39) | 30 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Cirrhotic (n=33,19,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Transition (n=33,19,2) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Advanced (n=33,19,2) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Mild (n=33,19,2) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, No fibrosis (n=33,19,2) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Cirrhotic (n=98,42,8) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Transition (n=98,42,8) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Advanced (n=98,42,8) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Mild (n=98,42,8) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, No fibrosis (n=98,42,8) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Cirrhotic (n=59,27,2) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Transition (n=59,27,2) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Advanced (n=59,27,2) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Mild (n=59,27,2) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, No fibrosis (n=59,27,2) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Cirrhotic (n=6,3,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Transition (n=6,3,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Mild (n=6,3,1) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, No fibrosis (n=6,3,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Cirrhotic (n=527,343,52) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Transition (n=527,343,52) | 43 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Advanced (n=527,343,52) | 83 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Mild (n=527,343,52) | 155 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, No fibrosis (n=527,343,52) | 44 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Cirrhotic (n=98,42,8) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Advanced (n=331,252,39) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Cirrhotic (n=6,3,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, No fibrosis (n=33,19,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Cirrhotic (n=331,252,39) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Transition (n=6,3,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Mild (n=33,19,2) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Advanced (n=33,19,2) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Advanced (n=6,3,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Transition (n=33,19,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Advanced (n=527,343,52) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Mild (n=6,3,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Cirrhotic (n=33,19,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Transition (n=331,252,39) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, No fibrosis (n=6,3,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, No fibrosis (n=331,252,39) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, No fibrosis (n=527,343,52) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Cirrhotic (n=59,27,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, No fibrosis (n=98,42,8) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Cirrhotic (n=527,343,52) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Transition (n=59,27,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Mild (n=98,42,8) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Mild (n=331,252,39) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Advanced (n=59,27,2) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Advanced (n=98,42,8) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Mild (n=527,343,52) | 24 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Mild (n=59,27,2) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Transition (n=98,42,8) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Transition (n=527,343,52) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, No fibrosis (n=59,27,2) | 0 participants |
Comparison: G1p-value: 0.8686Jonckheere-Terpstra Test
Comparison: G2p-value: 0.3135Jonckheere-Terpstra Test
Comparison: G3p-value: 0.0578Jonckheere-Terpstra Test
Comparison: G4p-value: 0.5833Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.161Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.2925Jonckheere-Terpstra Test
Primary
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage (Stage F0, Stage F1, Stage F2, Stage F3, or Stage F4) were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F0 (n=25,16,3) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F1 (n=291,256,35) | 72 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F0 (n=3,4,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F1 (n=25,16,3) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F4 (n=200,217,31) | 21 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F4 (n=30,14,0) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F2 (n=25,16,3) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F3 (n=291,256,35) | 57 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F3 (n=30,14,0) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F3 (n=25,16,3) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F0 (n=291,256,35) | 19 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F2 (n=30,14,0) | 17 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F4 (n=25,16,3) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F0 (n=33,5,1) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F1 (n=30,14,0) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F0 (n=30,14,0) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F2 (n=200,217,31) | 74 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F4 (n=3,4,0) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F1 (n=33,5,1) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F1 (n=200,217,31) | 46 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F3 (n=3,4,0) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F2 (n=33,5,1) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F2 (n=291,256,35) | 107 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F0 (n=200,217,31) | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F3 (n=33,5,1) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F3 (n=200,217,31) | 45 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F2 (n=3,4,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F4 (n=33,5,1) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F4 (n=291,256,35) | 36 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F1 (n=3,4,0) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F2 (n=3,4,0) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F0 (n=200,217,31) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F1 (n=200,217,31) | 50 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F2 (n=200,217,31) | 74 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F3 (n=200,217,31) | 48 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F4 (n=200,217,31) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F0 (n=33,5,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F1 (n=33,5,1) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F2 (n=33,5,1) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F3 (n=33,5,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F4 (n=33,5,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F0 (n=25,16,3) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F1 (n=25,16,3) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F2 (n=25,16,3) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F3 (n=25,16,3) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F4 (n=25,16,3) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F0 (n=30,14,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F1 (n=30,14,0) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F2 (n=30,14,0) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F3 (n=30,14,0) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F4 (n=30,14,0) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F0 (n=3,4,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F1 (n=3,4,0) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F3 (n=3,4,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F4 (n=3,4,0) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F0 (n=291,256,35) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F1 (n=291,256,35) | 62 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F2 (n=291,256,35) | 88 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F3 (n=291,256,35) | 51 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F4 (n=291,256,35) | 35 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F0 (n=25,16,3) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F2 (n=200,217,31) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F0 (n=3,4,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F4 (n=33,5,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F0 (n=200,217,31) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F1 (n=3,4,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F3 (n=33,5,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F2 (n=33,5,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F2 (n=3,4,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F1 (n=33,5,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F2 (n=291,256,35) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F3 (n=3,4,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G2, Stage F0 (n=33,5,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F1 (n=200,217,31) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Other, Stage F4 (n=3,4,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F4 (n=200,217,31) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F4 (n=291,256,35) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F0 (n=30,14,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F4 (n=25,16,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F0 (n=291,256,35) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F1 (n=30,14,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F3 (n=25,16,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G1, Stage F3 (n=200,217,31) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F2 (n=30,14,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F2 (n=25,16,3) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F3 (n=291,256,35) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F3 (n=30,14,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G3, Stage F1 (n=25,16,3) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | Total, Stage F1 (n=291,256,35) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Experienced | G4, Stage F4 (n=30,14,0) | 0 participants |
Comparison: G1p-value: 0.8622Jonckheere-Terpstra Test
Comparison: G2p-value: 0.1622Jonckheere-Terpstra Test
Comparison: G3p-value: 0.2566Jonckheere-Terpstra Test
Comparison: G4p-value: 0.1574Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.5784Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.6603Jonckheere-Terpstra Test
Primary
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver fibrosis stage (Stage F0, Stage F1, Stage F2, Stage F3, or Stage F4) were obtained from medical records. Liver fibrosis stage was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F0 (n=42,20,4) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F1 (n=277,187,28) | 101 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F0 (n=4,1,1) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F1 (n=42,20,4) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F4 (n=168,139,21) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F4 (n=43,20,1) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F2 (n=42,20,4) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F3 (n=277,187,28) | 39 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F3 (n=43,20,1) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F3 (n=42,20,4) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F0 (n=277,187,28) | 22 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F2 (n=43,20,1) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F4 (n=42,20,4) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F0 (n=20,7,1) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F1 (n=43,20,1) | 22 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F0 (n=43,20,1) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F2 (n=168,139,21) | 59 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F4 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F1 (n=20,7,1) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F1 (n=168,139,21) | 59 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F3 (n=4,1,1) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F2 (n=20,7,1) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F2 (n=277,187,28) | 89 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F0 (n=168,139,21) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F3 (n=20,7,1) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F3 (n=168,139,21) | 22 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F2 (n=4,1,1) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F4 (n=20,7,1) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F4 (n=277,187,28) | 26 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F1 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F2 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F0 (n=168,139,21) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F1 (n=168,139,21) | 45 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F2 (n=168,139,21) | 43 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F3 (n=168,139,21) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F4 (n=168,139,21) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F0 (n=20,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F1 (n=20,7,1) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F2 (n=20,7,1) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F3 (n=20,7,1) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F4 (n=20,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F0 (n=42,20,4) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F1 (n=42,20,4) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F2 (n=42,20,4) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F3 (n=42,20,4) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F4 (n=42,20,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F0 (n=43,20,1) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F1 (n=43,20,1) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F2 (n=43,20,1) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F3 (n=43,20,1) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F4 (n=43,20,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F0 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F1 (n=4,1,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F3 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F4 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F0 (n=277,187,28) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F1 (n=277,187,28) | 64 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F2 (n=277,187,28) | 57 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F3 (n=277,187,28) | 30 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F4 (n=277,187,28) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F0 (n=42,20,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F2 (n=168,139,21) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F0 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F4 (n=20,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F0 (n=168,139,21) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F1 (n=4,1,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F3 (n=20,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F2 (n=20,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F2 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F1 (n=20,7,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F2 (n=277,187,28) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F3 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G2, Stage F0 (n=20,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F1 (n=168,139,21) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Other, Stage F4 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F4 (n=168,139,21) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F4 (n=277,187,28) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F0 (n=43,20,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F4 (n=42,20,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F0 (n=277,187,28) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F1 (n=43,20,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F3 (n=42,20,4) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G1, Stage F3 (n=168,139,21) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F2 (n=43,20,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F2 (n=42,20,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F3 (n=277,187,28) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F3 (n=43,20,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G3, Stage F1 (n=42,20,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | Total, Stage F1 (n=277,187,28) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Fibrosis Stage and HCV RNA Genotype: Treatment-Naive | G4, Stage F4 (n=43,20,1) | 0 participants |
Comparison: G1p-value: 0.9887Jonckheere-Terpstra Test
Comparison: G2p-value: 0.5507Jonckheere-Terpstra Test
Comparison: G3p-value: 0.0175Jonckheere-Terpstra Test
Comparison: G4p-value: 0.2246Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.3519Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.714Jonckheere-Terpstra Test
Primary
Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype (Genotype 1 \[G1\], Genotype 2 \[G2\], Genotype 3 \[G3\], Genotype 4 \[G4\], and all other genotypes \[Other\]) and cirrhosis status ('Cirrhosis/transition to cirrhosis' or 'No cirrhosis') were obtained from medical records. Cirrhosis status was based upon previous biopsy or noninvasive assessment captured prior to treatment, if applicable.
Time frame: Study Visit 1 (single study visit)
Population: Core Analysis Population (Treatment-Naive): Only participants who had not received prior treatment for CHC were included in the analysis; n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G1, Cirrhosis (n=499,928,269) | 111 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G1, No cirrhosis (n=499,928,269) | 388 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G2, Cirrhosis (n=126,157,37) | 23 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G2, No cirrhosis (n=126,157,37) | 103 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G3, Cirrhosis (n=231,276,65) | 76 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G3, No cirrhosis (n=231,276,65) | 155 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G4, Cirrhosis (n=92,129,38) | 29 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G4, No cirrhosis (n=92,129,38) | 63 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | Other, Cirrhosis (n=28,21,6) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | Other, No cirrhosis (n=28,21,6) | 19 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | Total, Cirrhosis (n=976,1511,415) | 248 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | Total, No cirrhosis (n=976,1511,415) | 728 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | Total, No cirrhosis (n=976,1511,415) | 1121 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G1, Cirrhosis (n=499,928,269) | 255 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G4, Cirrhosis (n=92,129,38) | 35 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | Other, Cirrhosis (n=28,21,6) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G1, No cirrhosis (n=499,928,269) | 673 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G3, No cirrhosis (n=231,276,65) | 209 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | Total, Cirrhosis (n=976,1511,415) | 390 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G2, Cirrhosis (n=126,157,37) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G4, No cirrhosis (n=92,129,38) | 94 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G3, Cirrhosis (n=231,276,65) | 67 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G2, No cirrhosis (n=126,157,37) | 130 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | Other, No cirrhosis (n=28,21,6) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G2, No cirrhosis (n=126,157,37) | 34 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G3, Cirrhosis (n=231,276,65) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | Other, No cirrhosis (n=28,21,6) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G3, No cirrhosis (n=231,276,65) | 47 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G4, Cirrhosis (n=92,129,38) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G4, No cirrhosis (n=92,129,38) | 28 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | Total, Cirrhosis (n=976,1511,415) | 119 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G1, Cirrhosis (n=499,928,269) | 87 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G1, No cirrhosis (n=499,928,269) | 182 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | Other, Cirrhosis (n=28,21,6) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | G2, Cirrhosis (n=126,157,37) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive | Total, No cirrhosis (n=976,1511,415) | 296 participants |
Comparison: G1p-value: 0.0018Cochran-Armitage Trend Test
Comparison: G2p-value: 0.2289Cochran-Armitage Trend Test
Comparison: G3p-value: 0.1112Cochran-Armitage Trend Test
Comparison: G4p-value: 0.4681Cochran-Armitage Trend Test
Comparison: Other genotypesp-value: 0.4828Cochran-Armitage Trend Test
Comparison: Total genotypesp-value: 0.2702Cochran-Armitage Trend Test
Secondary
BMI by IL28B Genotype rs12979860: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including height and pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Each participant's BMI was calculated as weight divided by height-squared, expressed in kg/m\^2, and mean BMI was calculated by averaging the values of all participants within each arm.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced).
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | BMI by IL28B Genotype rs12979860: Treatment-Experienced | 25.8 kg/m^2 |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | BMI by IL28B Genotype rs12979860: Treatment-Experienced | 26.4 kg/m^2 |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | BMI by IL28B Genotype rs12979860: Treatment-Experienced | 26.3 kg/m^2 |
p-value: 0.0526Jonckheere-Terpstra Test
Secondary
BMI by IL28B Genotype rs8099917: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including height and pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Each participant's BMI was calculated as weight divided by height-squared, expressed in kg/m\^2, and mean BMI was calculated by averaging the values of all participants within each arm.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced).
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | BMI by IL28B Genotype rs8099917: Treatment-Experienced | 26.0 kg/m^2 |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | BMI by IL28B Genotype rs8099917: Treatment-Experienced | 26.4 kg/m^2 |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | BMI by IL28B Genotype rs8099917: Treatment-Experienced | 26.4 kg/m^2 |
p-value: 0.0842Jonckheere-Terpstra Test
Secondary
BMI by IL28B Genotype rs8099917: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including height and pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Each participant's BMI was calculated as weight divided by height-squared, expressed in kg/m\^2, and mean BMI was calculated by averaging the values of all participants within each arm.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive).
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | BMI by IL28B Genotype rs8099917: Treatment-Naive | 26.0 kg/m^2 |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | BMI by IL28B Genotype rs8099917: Treatment-Naive | 26.0 kg/m^2 |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | BMI by IL28B Genotype rs8099917: Treatment-Naive | 25.4 kg/m^2 |
p-value: 0.7918Jonckheere-Terpstra Test
Secondary
Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. ALT level was obtained from medical records captured prior to treatment, if applicable. Each participant's ALT ratio was calculated as ALT level divided by the upper limit of normal (55 international units per liter \[IU/L\] for males and 30 IU/L for females). Mean ALT ratio was calculated by averaging the values of all participants within each arm.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G1 (n=488,914,269) | 2.09 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G2 (n=123,152,37) | 2.42 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G3 (n=228,272,65) | 2.80 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G4 (n=88,121,38) | 2.00 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Other (n=28,21,7) | 1.46 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Total (n=955,1480,416) | 2.28 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Total (n=955,1480,416) | 1.88 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G1 (n=488,914,269) | 1.77 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G4 (n=88,121,38) | 1.66 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Other (n=28,21,7) | 1.72 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G2 (n=123,152,37) | 1.96 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G3 (n=228,272,65) | 2.32 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G2 (n=123,152,37) | 1.21 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G3 (n=228,272,65) | 2.05 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Total (n=955,1480,416) | 1.65 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G4 (n=88,121,38) | 1.65 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G1 (n=488,914,269) | 1.63 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Other (n=28,21,7) | 1.33 ratio |
Comparison: G1p-value: 0.0007Jonckheere-Terpstra Test
Comparison: G2p-value: 0.0061Jonckheere-Terpstra Test
Comparison: G3p-value: <0.0001Jonckheere-Terpstra Test
Comparison: G4p-value: 0.3885Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.3597Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: <0.0001Jonckheere-Terpstra Test
Secondary
Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. ALT level was obtained from medical records captured prior to treatment, if applicable. Each participant's ALT ratio was calculated as ALT level divided by the upper limit of normal (55 IU/L for males and 30 IU/L for females). Mean ALT ratio was calculated by averaging the values of all participants within each arm.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G1 (n=241,528,184) | 3.00 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G2 (n=80,32,9) | 3.45 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G3 (n=45,66,17) | 3.06 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G4 (n=23,47,17) | 1.65 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Other (n=9,13,2) | 2.99 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Total (n=398,686,229) | 3.02 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Total (n=398,686,229) | 2.13 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G1 (n=241,528,184) | 2.14 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G4 (n=23,47,17) | 1.79 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Other (n=9,13,2) | 1.82 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G2 (n=80,32,9) | 1.84 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G3 (n=45,66,17) | 2.49 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G2 (n=80,32,9) | 2.02 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G3 (n=45,66,17) | 2.27 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Total (n=398,686,229) | 1.96 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G4 (n=23,47,17) | 1.23 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G1 (n=241,528,184) | 2.00 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Other (n=9,13,2) | 2.17 ratio |
Comparison: G1p-value: <0.0001Jonckheere-Terpstra Test
Comparison: G2p-value: 0.0005Jonckheere-Terpstra Test
Comparison: G3p-value: 0.011Jonckheere-Terpstra Test
Comparison: G4p-value: 0.098Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.2264Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: <0.0001Jonckheere-Terpstra Test
Secondary
Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. ALT level was obtained from medical records captured prior to treatment, if applicable. Each participant's ALT ratio was calculated as ALT level divided by the upper limit of normal (55 IU/L for males and 30 IU/L for females). Mean ALT ratio was calculated by averaging the values of all participants within each arm.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G1 (n=442,437,74) | 2.60 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G4 (n=54,33,0) | 1.58 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G3 (n=68,51,9) | 3.04 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Total (n=667,556,90) | 2.66 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Other (n=11,12,1) | 2.78 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G2 (n=92,23,6) | 3.26 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Other (n=11,12,1) | 1.75 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G1 (n=442,437,74) | 2.11 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G2 (n=92,23,6) | 1.79 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G3 (n=68,51,9) | 2.29 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G4 (n=54,33,0) | 1.76 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Total (n=667,556,90) | 2.09 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Total (n=667,556,90) | 2.01 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G4 (n=54,33,0) | NA ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G1 (n=442,437,74) | 2.00 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Other (n=11,12,1) | 3.32 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G3 (n=68,51,9) | 1.90 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G2 (n=92,23,6) | 2.04 ratio |
Comparison: G1p-value: 0.0007Jonckheere-Terpstra Test
Comparison: G2p-value: 0.002Jonckheere-Terpstra Test
Comparison: G3p-value: 0.0013Jonckheere-Terpstra Test
Comparison: G4p-value: 0.7166Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.3217Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: <0.0001Jonckheere-Terpstra Test
Secondary
Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. ALT level was obtained from medical records captured prior to treatment, if applicable. Each participant's ALT ratio was calculated as ALT level divided by the upper limit of normal (55 IU/L for males and 30 IU/L for females). Mean ALT ratio was calculated by averaging the values of all participants within each arm.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G1 (n=818,737,116) | 2.02 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G2 (n=192,108,12) | 2.09 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G3 (n=355,183,27) | 2.72 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G4 (n=155,83,9) | 1.78 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Other (n=37,15,4) | 1.66 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Total (n=1557,1126,168) | 2.16 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Total (n=1557,1126,168) | 1.78 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G1 (n=818,737,116) | 1.67 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G4 (n=155,83,9) | 1.84 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Other (n=37,15,4) | 1.25 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G2 (n=192,108,12) | 2.06 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G3 (n=355,183,27) | 2.08 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G2 (n=192,108,12) | 1.31 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G3 (n=355,183,27) | 2.03 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Total (n=1557,1126,168) | 1.67 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G4 (n=155,83,9) | 1.20 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G1 (n=818,737,116) | 1.67 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Other (n=37,15,4) | 1.56 ratio |
Comparison: G1p-value: 0.0098Jonckheere-Terpstra Test
Comparison: G2p-value: 0.6291Jonckheere-Terpstra Test
Comparison: G3p-value: 0.0013Jonckheere-Terpstra Test
Comparison: G4p-value: 0.5588Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.9932Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: <0.0001Jonckheere-Terpstra Test
Secondary
Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. AST level was obtained from medical records captured prior to treatment, if applicable. Each participant's AST ratio was calculated as AST level divided by the upper limit of normal (40 IU/L for males and 25 IU/L for females). Mean AST ratio was calculated by averaging the values of all participants within each arm.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G1 (n=480,891,264) | 1.62 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G2 (n=122,151,37) | 1.93 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G3 (n=227,266,64) | 2.17 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G4 (n=83,118,33) | 1.71 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Other (n=28,18,7) | 1.41 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Total (n=940,1444,405) | 1.80 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Total (n=940,1444,405) | 1.64 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G1 (n=480,891,264) | 1.59 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G4 (n=83,118,33) | 1.54 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Other (n=28,18,7) | 1.63 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G2 (n=122,151,37) | 1.63 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G3 (n=227,266,64) | 1.88 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G2 (n=122,151,37) | 1.06 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G3 (n=227,266,64) | 1.44 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Total (n=940,1444,405) | 1.41 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G4 (n=83,118,33) | 1.41 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G1 (n=480,891,264) | 1.46 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Other (n=28,18,7) | 1.29 ratio |
Comparison: G1p-value: 0.1894Jonckheere-Terpstra Test
Comparison: G2p-value: 0.0054Jonckheere-Terpstra Test
Comparison: G3p-value: <0.0001Jonckheere-Terpstra Test
Comparison: G4p-value: 0.536Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.2185Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: <0.0001Jonckheere-Terpstra Test
Secondary
Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. AST level was obtained from medical records captured prior to treatment, if applicable. Each participant's AST ratio was calculated as AST level divided by the upper limit of normal (40 IU/L for males and 25 IU/L for females). Mean AST ratio was calculated by averaging the values of all participants within each arm.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G1 (n=234,501,173) | 2.27 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G2 (n=80,32,9) | 2.49 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G3 (n=45,63,17) | 2.42 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G4 (n=23,46,17) | 1.31 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Other (n=9,13,2) | 1.86 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Total (n=391,655,218) | 2.27 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Total (n=391,655,218) | 1.76 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G1 (n=234,501,173) | 1.78 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G4 (n=23,46,17) | 1.52 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Other (n=9,13,2) | 1.47 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G2 (n=80,32,9) | 1.33 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G3 (n=45,63,17) | 2.07 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G2 (n=80,32,9) | 1.58 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G3 (n=45,63,17) | 1.71 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Total (n=391,655,218) | 1.63 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G4 (n=23,46,17) | 1.36 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G1 (n=234,501,173) | 1.65 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Other (n=9,13,2) | 1.09 ratio |
Comparison: G1p-value: 0.0002Jonckheere-Terpstra Test
Comparison: G2p-value: 0.0003Jonckheere-Terpstra Test
Comparison: G3p-value: 0.0106Jonckheere-Terpstra Test
Comparison: G4p-value: 0.7821Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.2372Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: <0.0001Jonckheere-Terpstra Test
Secondary
Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. AST level was obtained from medical records captured prior to treatment, if applicable. Each participant's AST ratio was calculated as AST level divided by the upper limit of normal (40 IU/L for males and 25 IU/L for females). Mean AST ratio was calculated by averaging the values of all participants within each arm.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G1 (n=423,415,70) | 2.01 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G4 (n=54,32,0) | 1.30 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G3 (n=67,49,9) | 2.36 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Total (n=647,531,86) | 2.03 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Other (n=11,12,1) | 1.79 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G2 (n=92,23,6) | 2.34 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Other (n=11,12,1) | 1.41 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G1 (n=423,415,70) | 1.78 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G2 (n=92,23,6) | 1.36 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G3 (n=67,49,9) | 1.96 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G4 (n=54,32,0) | 1.65 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Total (n=647,531,86) | 1.77 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Total (n=647,531,86) | 1.65 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G4 (n=54,32,0) | NA ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G1 (n=423,415,70) | 1.66 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Other (n=11,12,1) | 1.45 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G3 (n=67,49,9) | 1.63 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G2 (n=92,23,6) | 1.61 ratio |
Comparison: G1p-value: 0.0247Jonckheere-Terpstra Test
Comparison: G2p-value: 0.0034Jonckheere-Terpstra Test
Comparison: G3p-value: 0.0017Jonckheere-Terpstra Test
Comparison: G4p-value: 0.3346Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.3215Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.0003Jonckheere-Terpstra Test
Secondary
Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. AST level was obtained from medical records captured prior to treatment, if applicable. Each participant's AST ratio was calculated as AST level divided by the upper limit of normal (40 IU/L for males and 25 IU/L for females). Mean AST ratio was calculated by averaging the values of all participants within each arm.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G1 (n=800,724,111) | 1.65 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G2 (n=190,108,12) | 1.71 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G3 (n=350,181,26) | 2.13 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G4 (n=148,79,7) | 1.54 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Other (n=36,13,4) | 1.41 ratio |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Total (n=1524,1105,160) | 1.75 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Total (n=1524,1105,160) | 1.57 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G1 (n=800,724,111) | 1.51 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G4 (n=148,79,7) | 1.69 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Other (n=36,13,4) | 1.62 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G2 (n=190,108,12) | 1.66 ratio |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G3 (n=350,181,26) | 1.68 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G2 (n=190,108,12) | 1.37 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G3 (n=350,181,26) | 1.42 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Total (n=1524,1105,160) | 1.46 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G4 (n=148,79,7) | 1.14 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G1 (n=800,724,111) | 1.49 ratio |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Other (n=36,13,4) | 1.51 ratio |
Comparison: G1p-value: 0.0688Jonckheere-Terpstra Test
Comparison: G2p-value: 0.4367Jonckheere-Terpstra Test
Comparison: G3p-value: <0.0001Jonckheere-Terpstra Test
Comparison: G4p-value: 0.1951Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.2927Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.0013Jonckheere-Terpstra Test
Secondary
Mean Body Mass Index (BMI) by IL28B Genotype rs12979860: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including height and pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Each participant's BMI was calculated as weight divided by height-squared, expressed in kilograms per meter-squared (kg/m\^2), and mean BMI was calculated by averaging the values of all participants within each arm.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive).
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Body Mass Index (BMI) by IL28B Genotype rs12979860: Treatment-Naive | 25.8 kg/m^2 |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Body Mass Index (BMI) by IL28B Genotype rs12979860: Treatment-Naive | 26.0 kg/m^2 |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Body Mass Index (BMI) by IL28B Genotype rs12979860: Treatment-Naive | 26.0 kg/m^2 |
p-value: 0.2617Jonckheere-Terpstra Test
Secondary
Mean Body Weight by IL28B Genotype rs12979860: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Mean body weight was calculated by averaging the values of all participants within each arm and expressed in kg.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced).
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Body Weight by IL28B Genotype rs12979860: Treatment-Experienced | 72.7 kg |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Body Weight by IL28B Genotype rs12979860: Treatment-Experienced | 75.0 kg |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Body Weight by IL28B Genotype rs12979860: Treatment-Experienced | 75.1 kg |
p-value: 0.002Jonckheere-Terpstra Test
Secondary
Mean Body Weight by IL28B Genotype rs12979860: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Mean body weight was calculated by averaging the values of all participants within each arm and expressed in kilograms (kg).
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive).
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Body Weight by IL28B Genotype rs12979860: Treatment-Naive | 74.6 kg |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Body Weight by IL28B Genotype rs12979860: Treatment-Naive | 74.4 kg |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Body Weight by IL28B Genotype rs12979860: Treatment-Naive | 74.2 kg |
p-value: 0.5468Jonckheere-Terpstra Test
Secondary
Mean Body Weight by IL28B Genotype rs8099917: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Mean body weight was calculated by averaging the values of all participants within each arm and expressed in kg.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced).
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Body Weight by IL28B Genotype rs8099917: Treatment-Experienced | 73.7 kg |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Body Weight by IL28B Genotype rs8099917: Treatment-Experienced | 75.2 kg |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Body Weight by IL28B Genotype rs8099917: Treatment-Experienced | 73.8 kg |
p-value: 0.0663Jonckheere-Terpstra Test
Secondary
Mean Body Weight by IL28B Genotype rs8099917: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including pre-treatment body weight, were obtained from medical records and/or participant interview at the Study Visit. Mean body weight was calculated by averaging the values of all participants within each arm and expressed in kg.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive).
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Body Weight by IL28B Genotype rs8099917: Treatment-Naive | 74.8 kg |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Body Weight by IL28B Genotype rs8099917: Treatment-Naive | 74.2 kg |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Body Weight by IL28B Genotype rs8099917: Treatment-Naive | 72.8 kg |
p-value: 0.1623Jonckheere-Terpstra Test
Secondary
Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA level was obtained from medical records. Mean HCV RNA level was calculated by averaging the values of all participants within each arm and expressed in log10 IU/mL.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G1 (n=244,591,196) | 6.06 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G2 (n=68,30,10) | 5.39 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G3 (n=38,53,12) | 5.97 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G4 (n=22,56,20) | 5.49 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Other (n=10,14,2) | 5.59 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Total (n=382,744,240) | 5.89 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Total (n=382,744,240) | 5.93 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G1 (n=244,591,196) | 5.98 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G4 (n=22,56,20) | 5.58 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Other (n=10,14,2) | 5.63 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G2 (n=68,30,10) | 6.07 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G3 (n=38,53,12) | 5.78 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G2 (n=68,30,10) | 5.64 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G3 (n=38,53,12) | 5.60 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Total (n=382,744,240) | 5.80 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G4 (n=22,56,20) | 5.66 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G1 (n=244,591,196) | 5.84 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Other (n=10,14,2) | 4.90 log10 IU/mL |
Comparison: G1p-value: <0.0001Jonckheere-Terpstra Test
Comparison: G2p-value: 0.0145Jonckheere-Terpstra Test
Comparison: G3p-value: 0.1027Jonckheere-Terpstra Test
Comparison: G4p-value: 0.5998Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.2935Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.0039Jonckheere-Terpstra Test
Secondary
Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA level was obtained from medical records. Mean HCV RNA level was calculated by averaging the values of all participants within each arm and expressed in log10 international units per milliliter (log10 IU/mL).
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G1 (n=481,903,263) | 5.96 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G2 (n=121,157,36) | 5.95 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G3 (n=226,268,63) | 6.02 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G4 (n=84,123,38) | 5.68 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Other (n=16,16,7) | 5.46 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Total (n=928,1467,407) | 5.94 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Total (n=928,1467,407) | 5.83 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G1 (n=481,903,263) | 5.89 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G4 (n=84,123,38) | 5.59 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Other (n=16,16,7) | 5.48 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G2 (n=121,157,36) | 5.76 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G3 (n=226,268,63) | 5.81 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G2 (n=121,157,36) | 5.92 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G3 (n=226,268,63) | 5.51 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Total (n=928,1467,407) | 5.68 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G4 (n=84,123,38) | 5.45 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G1 (n=481,903,263) | 5.72 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Other (n=16,16,7) | 5.58 log10 IU/mL |
Comparison: G1p-value: <0.0001Jonckheere-Terpstra Test
Comparison: G2p-value: 0.2887Jonckheere-Terpstra Test
Comparison: G3p-value: <0.0001Jonckheere-Terpstra Test
Comparison: G4p-value: 0.1634Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.8956Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: <0.0001Jonckheere-Terpstra Test
Secondary
Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA level was obtained from medical records. Mean HCV RNA level was calculated by averaging the values of all participants within each arm and expressed in log10 IU/mL.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G1 (n=469,480,82) | 6.04 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G2 (n=81,21,6) | 5.52 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G3 (n=59,39,5) | 5.87 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G4 (n=59,39,0) | 5.67 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Other (n=11,15,0) | 5.59 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Total (n=679,594,93) | 5.93 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Total (n=679,594,93) | 5.87 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G1 (n=469,480,82) | 5.92 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G4 (n=59,39,0) | 5.43 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Other (n=11,15,0) | 5.54 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G2 (n=81,21,6) | 5.97 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G3 (n=59,39,5) | 5.78 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G2 (n=81,21,6) | 5.49 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G3 (n=59,39,5) | 5.73 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Total (n=679,594,93) | 5.82 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G4 (n=59,39,0) | NA log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G1 (n=469,480,82) | 5.85 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Other (n=11,15,0) | NA log10 IU/mL |
Comparison: G1p-value: <0.0001Jonckheere-Terpstra Test
Comparison: G2p-value: 0.189Jonckheere-Terpstra Test
Comparison: G3p-value: 0.5793Jonckheere-Terpstra Test
Comparison: G4p-value: 0.0847Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.5506Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.002Jonckheere-Terpstra Test
Secondary
Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA level was obtained from medical records. Mean HCV RNA level was calculated by averaging the values of all participants within each arm and expressed in log10 IU/mL.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G1 (n=809,723,115) | 5.99 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G2 (n=191,111,12) | 5.90 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G3 (n=350,181,26) | 5.99 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G4 (n=155,82,8) | 5.64 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Other (n=24,11,4) | 5.53 log10 IU/mL |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Total (n=1529,1108,165) | 5.93 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Total (n=1529,1108,165) | 5.76 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G1 (n=809,723,115) | 5.82 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G4 (n=155,82,8) | 5.53 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Other (n=24,11,4) | 5.13 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G2 (n=191,111,12) | 5.74 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G3 (n=350,181,26) | 5.69 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G2 (n=191,111,12) | 6.20 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G3 (n=350,181,26) | 5.39 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Total (n=1529,1108,165) | 5.63 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G4 (n=155,82,8) | 5.53 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G1 (n=809,723,115) | 5.61 log10 IU/mL |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Other (n=24,11,4) | 6.27 log10 IU/mL |
Comparison: G1p-value: <0.0001Jonckheere-Terpstra Test
Comparison: G2p-value: 0.2132Jonckheere-Terpstra Test
Comparison: G3p-value: <0.0001Jonckheere-Terpstra Test
Comparison: G4p-value: 0.3031Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.955Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: <0.0001Jonckheere-Terpstra Test
Secondary
Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Platelet count was obtained from medical records captured prior to treatment, if applicable. Mean platelet count was calculated by averaging the values of all participants within each arm and expressed in 10\^9 cells/L.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G1 (n=233,501,167) | 180 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G2 (n=74,29,8) | 166 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G3 (n=46,65,17) | 182 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G4 (n=22,43,17) | 194 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Other (n=8,13,1) | 173. 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Total (n=383,651,210) | 178 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Total (n=383,651,210) | 194 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G1 (n=233,501,167) | 196 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G4 (n=22,43,17) | 184 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Other (n=8,13,1) | 202 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G2 (n=74,29,8) | 181 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G3 (n=46,65,17) | 191 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G2 (n=74,29,8) | 165 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G3 (n=46,65,17) | 191 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Total (n=383,651,210) | 194 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G4 (n=22,43,17) | 185 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | G1 (n=233,501,167) | 197 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced | Other (n=8,13,1) | 209 10^9 cells/L |
Comparison: G1p-value: 0.0002Jonckheere-Terpstra Test
Comparison: G2p-value: 0.2017Jonckheere-Terpstra Test
Comparison: G3p-value: 0.5878Jonckheere-Terpstra Test
Comparison: G4p-value: 0.4144Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.4492Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: <0.0001Jonckheere-Terpstra Test
Secondary
Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Platelet count was obtained from medical records captured prior to treatment, if applicable. Mean platelet count was calculated by averaging the values of all participants within each arm and expressed in 10\^9 cells per liter (10\^9 cells/L).
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G1 (n=483,900,269) | 200 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G2 (n=121,147,37) | 190 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G3 (n=225,268,64) | 186 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G4 (n=85,124,38) | 198 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Other (n=25,19,7) | 216 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Total (n=939,1458,415) | 196 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Total (n=939,1458,415) | 203 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G1 (n=483,900,269) | 204 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G4 (n=85,124,38) | 191 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Other (n=25,19,7) | 203 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G2 (n=121,147,37) | 212 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G3 (n=225,268,64) | 201 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G2 (n=121,147,37) | 203 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G3 (n=225,268,64) | 193 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Total (n=939,1458,415) | 199 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G4 (n=85,124,38) | 189 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | G1 (n=483,900,269) | 201 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive | Other (n=25,19,7) | 195 10^9 cells/L |
Comparison: G1p-value: 0.3609Jonckheere-Terpstra Test
Comparison: G2p-value: 0.0018Jonckheere-Terpstra Test
Comparison: G3p-value: 0.0356Jonckheere-Terpstra Test
Comparison: G4p-value: 0.7044Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.8578Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.0076Jonckheere-Terpstra Test
Secondary
Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Platelet count was obtained from medical records captured prior to treatment, if applicable. Mean platelet count was calculated by averaging the values of all participants within each arm and expressed in 10\^9 cells/L.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G1 (n=426,406,69) | 186 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G2 (n=84,21,6) | 167 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G3 (n=68,51,9) | 180 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G4 (n=53,29,0) | 189 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Other (n=10,12,0) | 194 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Total (n=641,519,64) | 183 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Total (n=641,519,64) | 197 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G1 (n=426,406,69) | 199 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G4 (n=53,29,0) | 182 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Other (n=10,12,0) | 190 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G2 (n=84,21,6) | 184 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G3 (n=68,51,9) | 199 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G2 (n=84,21,6) | 162 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G3 (n=68,51,9) | 182 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Total (n=641,519,64) | 187 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G4 (n=53,29,0) | NA 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | G1 (n=426,406,69) | 190 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced | Other (n=10,12,0) | NA 10^9 cells/L |
Comparison: G1p-value: 0.0059Jonckheere-Terpstra Test
Comparison: G2p-value: 0.2808Jonckheere-Terpstra Test
Comparison: G3p-value: 0.2401Jonckheere-Terpstra Test
Comparison: G4p-value: 0.2993Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.5529Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.0005Jonckheere-Terpstra Test
Secondary
Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Platelet count was obtained from medical records captured prior to treatment, if applicable. Mean platelet count was calculated by averaging the values of all participants within each arm and expressed in 10\^9 cells/L.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G1 (n=810,727,115) | 200 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G2 (n=188,105,12) | 199 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G3 (n=351,179,27) | 191 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G4 (n=156,81,10) | 195 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Other (n=33,14,4) | 216 10^9 cells/L |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Total (n=1538,1106,168) | 197 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Total (n=1538,1106,168) | 203 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G1 (n=810,727,115) | 205 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G4 (n=156,81,10) | 190 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Other (n=33,14,4) | 193 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G2 (n=188,105,12) | 209 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G3 (n=351,179,27) | 201 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G2 (n=188,105,12) | 194 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G3 (n=351,179,27) | 196 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Total (n=1538,1106,168) | 200 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G4 (n=156,81,10) | 185 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | G1 (n=810,727,115) | 203 10^9 cells/L |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive | Other (n=33,14,4) | 199 10^9 cells/L |
Comparison: G4p-value: 0.4162Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.9305Jonckheere-Terpstra Test
Comparison: G1p-value: 0.0671Jonckheere-Terpstra Test
Comparison: G2p-value: 0.1009Jonckheere-Terpstra Test
Comparison: G3p-value: 0.0635Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.0041Jonckheere-Terpstra Test
Secondary
Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including self-reported ethnic origin, were obtained from medical records and/or participant interview at the Study Visit.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Native American/American Indian | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Asian/Oriental | 161 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Caucasian/white | 314 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Black | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Other | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Asian/Oriental | 42 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Caucasian/white | 807 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Black | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Native American/American Indian | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Other | 43 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Other | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Native American/American Indian | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Caucasian/white | 259 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Asian/Oriental | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced | Black | 15 participants |
p-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including self-reported ethnic origin, were obtained from medical records and/or participant interview at the Study Visit.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Native American/American Indian | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Asian/Oriental | 89 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Caucasian/white | 860 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Black | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Other | 24 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Asian/Oriental | 83 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Caucasian/white | 1349 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Black | 24 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Native American/American Indian | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Other | 61 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Other | 18 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Native American/American Indian | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Caucasian/white | 373 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Asian/Oriental | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive | Black | 19 participants |
p-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including gender, were obtained from medical records and/or participant interview at the Study Visit.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Experienced | Male | 287 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Experienced | Female | 203 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Experienced | Male | 509 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Experienced | Female | 405 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Experienced | Male | 169 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Experienced | Female | 127 participants |
p-value: 0.5651Cochran-Armitage Trend Test
Secondary
Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including gender, were obtained from medical records and/or participant interview at the Study Visit.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Naive | Male | 582 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Naive | Female | 396 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Naive | Male | 802 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Naive | Female | 716 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Naive | Male | 224 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Naive | Female | 196 participants |
p-value: 0.0049Cochran-Armitage Trend Test
Secondary
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=295,703,239) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=295,703,239) | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=295,703,239) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=295,703,239) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, France (n=295,703,239) | 41 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=295,703,239) | 16 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=295,703,239) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=295,703,239) | 40 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=295,703,239) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=295,703,239) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=295,703,239) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=295,703,239) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=295,703,239) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=295,703,239) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=295,703,239) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=295,703,239) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=295,703,239) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=295,703,239) | 23 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=295,703,239) | 81 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=295,703,239) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=295,703,239) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=295,703,239) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=295,703,239) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=295,703,239) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, France (n=92,38,11) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=92,38,11) | 18 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=92,38,11) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=92,38,11) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=92,38,11) | 59 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=92,38,11) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=92,38,11) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=63,84,20) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=63,84,20) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=63,84,20) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, France (n=63,84,20) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=63,84,20) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=63,84,20) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=63,84,20) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=63,84,20) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=63,84,20) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=63,84,20) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=63,84,20) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=63,84,20) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=63,84,20) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=295,703,239) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=63,84,20) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=295,703,239) | 37 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=295,703,239) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=295,703,239) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=63,84,20) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=63,84,20) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=295,703,239) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=92,38,11) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, France (n=295,703,239) | 125 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=295,703,239) | 36 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=63,84,20) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=295,703,239) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=63,84,20) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=295,703,239) | 117 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=295,703,239) | 41 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=63,84,20) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=295,703,239) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=92,38,11) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=295,703,239) | 43 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=92,38,11) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=295,703,239) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=92,38,11) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, France (n=92,38,11) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=295,703,239) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, France (n=63,84,20) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=295,703,239) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=295,703,239) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=295,703,239) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=63,84,20) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=295,703,239) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=63,84,20) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=295,703,239) | 80 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=63,84,20) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=295,703,239) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=63,84,20) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=295,703,239) | 59 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=63,84,20) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=295,703,239) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=63,84,20) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=295,703,239) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=295,703,239) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=63,84,20) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=92,38,11) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=295,703,239) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=92,38,11) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=295,703,239) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=63,84,20) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=295,703,239) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, France (n=92,38,11) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=63,84,20) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=92,38,11) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=92,38,11) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=92,38,11) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=63,84,20) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=63,84,20) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=92,38,11) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=92,38,11) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=63,84,20) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=92,38,11) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=92,38,11) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=295,703,239) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=295,703,239) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=295,703,239) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=63,84,20) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, France (n=295,703,239) | 44 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=295,703,239) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=295,703,239) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=63,84,20) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=295,703,239) | 46 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=295,703,239) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=295,703,239) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=295,703,239) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=295,703,239) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, France (n=63,84,20) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=295,703,239) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=295,703,239) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=295,703,239) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=295,703,239) | 25 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=295,703,239) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=63,84,20) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=295,703,239) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=63,84,20) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=295,703,239) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=295,703,239) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=63,84,20) | 0 participants |
Comparison: G1p-value: <0.0001Chi-squared
Comparison: G2p-value: <0.0001Chi-squared
Comparison: G3p-value: 0.5522Chi-squared
Secondary
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=26,67,21) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=26,67,21) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=26,67,21) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, France (n=26,67,21) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=26,67,21) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=26,67,21) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=26,67,21) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=26,67,21) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=26,67,21) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=14,22,5) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, France (n=14,22,5) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=14,22,5) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=14,22,5) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=14,22,5) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=14,22,5) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=14,22,5) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=14,22,5) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=490,914,296) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=490,914,296) | 21 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=490,914,296) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=490,914,296) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=490,914,296) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, France (n=490,914,296) | 68 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=490,914,296) | 21 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=490,914,296) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=490,914,296) | 76 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=490,914,296) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=490,914,296) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=490,914,296) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=490,914,296) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=490,914,296) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=490,914,296) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=490,914,296) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=490,914,296) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=490,914,296) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=490,914,296) | 28 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=490,914,296) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=490,914,296) | 23 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=490,914,296) | 144 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=490,914,296) | 17 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=490,914,296) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=490,914,296) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=490,914,296) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=490,914,296) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=490,914,296) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=490,914,296) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=490,914,296) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=490,914,296) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=26,67,21) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=14,22,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=490,914,296) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=26,67,21) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=490,914,296) | 43 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=490,914,296) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=26,67,21) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=14,22,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=490,914,296) | 80 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=26,67,21) | 25 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=490,914,296) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=490,914,296) | 47 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=14,22,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=14,22,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, France (n=26,67,21) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=490,914,296) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=26,67,21) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=490,914,296) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=26,67,21) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=490,914,296) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=490,914,296) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=26,67,21) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=490,914,296) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=490,914,296) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=26,67,21) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=490,914,296) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=490,914,296) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=14,22,5) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=490,914,296) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=14,22,5) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, France (n=14,22,5) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, France (n=490,914,296) | 162 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=490,914,296) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=490,914,296) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=26,67,21) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=490,914,296) | 41 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=490,914,296) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=490,914,296) | 75 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=490,914,296) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=490,914,296) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=490,914,296) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=490,914,296) | 157 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=490,914,296) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=490,914,296) | 57 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=490,914,296) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=26,67,21) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=490,914,296) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=490,914,296) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=490,914,296) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=490,914,296) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, France (n=14,22,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=490,914,296) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=490,914,296) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=490,914,296) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=490,914,296) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=490,914,296) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=490,914,296) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=490,914,296) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=14,22,5) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=490,914,296) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=490,914,296) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=490,914,296) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=490,914,296) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=490,914,296) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=26,67,21) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=490,914,296) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=26,67,21) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=490,914,296) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, France (n=26,67,21) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=490,914,296) | 25 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=490,914,296) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=26,67,21) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=490,914,296) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=490,914,296) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=26,67,21) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=490,914,296) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=490,914,296) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, France (n=490,914,296) | 54 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=26,67,21) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=490,914,296) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=490,914,296) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=490,914,296) | 29 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=490,914,296) | 56 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=490,914,296) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=490,914,296) | 0 participants |
Comparison: G4p-value: 0.5117Chi-squared
Comparison: Other genotypesp-value: 0.3437Chi-squared
Comparison: Total genotypesp-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=500,930,272) | 54 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=500,930,272) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=500,930,272) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=500,930,272) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=500,930,272) | 44 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, France (n=500,930,272) | 48 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=500,930,272) | 30 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=500,930,272) | 22 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=500,930,272) | 101 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=500,930,272) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=500,930,272) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=500,930,272) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=500,930,272) | 16 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=500,930,272) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=500,930,272) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=500,930,272) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=500,930,272) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=500,930,272) | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=500,930,272) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=500,930,272) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=500,930,272) | 60 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=500,930,272) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=500,930,272) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=500,930,272) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=500,930,272) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=500,930,272) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=500,930,272) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=500,930,272) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=500,930,272) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=500,930,272) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=126,160,37) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=126,160,37) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, France (n=126,160,37) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=126,160,37) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=126,160,37) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=126,160,37) | 81 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=126,160,37) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=126,160,37) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=126,160,37) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=126,160,37) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=126,160,37) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=126,160,37) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=126,160,37) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=126,160,37) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=126,160,37) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=126,160,37) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=232,277,65) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=232,277,65) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=232,277,65) | 27 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, France (n=232,277,65) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=232,277,65) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=232,277,65) | 22 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=232,277,65) | 70 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=232,277,65) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=232,277,65) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=232,277,65) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=232,277,65) | 45 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=232,277,65) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=232,277,65) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=232,277,65) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=232,277,65) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=232,277,65) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=232,277,65) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=232,277,65) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=232,277,65) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=232,277,65) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=232,277,65) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=500,930,272) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=500,930,272) | 41 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=232,277,65) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=500,930,272) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=126,160,37) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=232,277,65) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=500,930,272) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=232,277,65) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=232,277,65) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=500,930,272) | 70 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=126,160,37) | 117 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, France (n=500,930,272) | 76 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=126,160,37) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=232,277,65) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=500,930,272) | 54 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=500,930,272) | 35 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=232,277,65) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=232,277,65) | 52 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=500,930,272) | 167 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=500,930,272) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=500,930,272) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=232,277,65) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=500,930,272) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=126,160,37) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=500,930,272) | 46 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=126,160,37) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=232,277,65) | 25 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=500,930,272) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=126,160,37) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=500,930,272) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=126,160,37) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, France (n=126,160,37) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=500,930,272) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=126,160,37) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, France (n=232,277,65) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=500,930,272) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=500,930,272) | 35 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=232,277,65) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=500,930,272) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=232,277,65) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=500,930,272) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=126,160,37) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=232,277,65) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=500,930,272) | 121 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=126,160,37) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=232,277,65) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=500,930,272) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=126,160,37) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=232,277,65) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=500,930,272) | 138 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=232,277,65) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=500,930,272) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=232,277,65) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=500,930,272) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=232,277,65) | 70 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=500,930,272) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=500,930,272) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=232,277,65) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=500,930,272) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=126,160,37) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=232,277,65) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=500,930,272) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=126,160,37) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=126,160,37) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=500,930,272) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=232,277,65) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=500,930,272) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=232,277,65) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=126,160,37) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, France (n=126,160,37) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=126,160,37) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=232,277,65) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=126,160,37) | 30 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=232,277,65) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=126,160,37) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=126,160,37) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=232,277,65) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=232,277,65) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=232,277,65) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=232,277,65) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=500,930,272) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=500,930,272) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=500,930,272) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=500,930,272) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=500,930,272) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=232,277,65) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, France (n=500,930,272) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=500,930,272) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=500,930,272) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=500,930,272) | 59 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=500,930,272) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=500,930,272) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=500,930,272) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=500,930,272) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=500,930,272) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=232,277,65) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=500,930,272) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=500,930,272) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=500,930,272) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, France (n=232,277,65) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=500,930,272) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=500,930,272) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=500,930,272) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=232,277,65) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=500,930,272) | 34 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=500,930,272) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=500,930,272) | 51 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=232,277,65) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=500,930,272) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=500,930,272) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=500,930,272) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=232,277,65) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=500,930,272) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=500,930,272) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=500,930,272) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=232,277,65) | 0 participants |
Comparison: G1p-value: 0.0103Chi-squared
Comparison: G2p-value: 0.8373Chi-squared
Comparison: G3p-value: 0.3672Chi-squared
Secondary
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=92,129,39) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=92,129,39) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=92,129,39) | 28 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, France (n=92,129,39) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=92,129,39) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=92,129,39) | 25 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=92,129,39) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=92,129,39) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=92,129,39) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=92,129,39) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=92,129,39) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=92,129,39) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=92,129,39) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=92,129,39) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=28,22,7) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, France (n=28,22,7) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=28,22,7) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=28,22,7) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=28,22,7) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=28,22,7) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=28,22,7) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=28,22,7) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=978,1518,420) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=978,1518,420) | 33 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=978,1518,420) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=978,1518,420) | 28 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=978,1518,420) | 74 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, France (n=978,1518,420) | 62 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=978,1518,420) | 41 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=978,1518,420) | 52 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=978,1518,420) | 277 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=978,1518,420) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=978,1518,420) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=978,1518,420) | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=978,1518,420) | 38 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=978,1518,420) | 18 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=978,1518,420) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=978,1518,420) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=978,1518,420) | 50 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=978,1518,420) | 16 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=978,1518,420) | 17 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=978,1518,420) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=978,1518,420) | 61 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=978,1518,420) | 28 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=978,1518,420) | 74 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=978,1518,420) | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=978,1518,420) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=978,1518,420) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=978,1518,420) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=978,1518,420) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=978,1518,420) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=978,1518,420) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=978,1518,420) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=92,129,39) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=978,1518,420) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=92,129,39) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=978,1518,420) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=978,1518,420) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=28,22,7) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=978,1518,420) | 122 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=92,129,39) | 28 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=978,1518,420) | 40 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=978,1518,420) | 60 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=28,22,7) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=28,22,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, France (n=92,129,39) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=978,1518,420) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=92,129,39) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=978,1518,420) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=92,129,39) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=978,1518,420) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=978,1518,420) | 60 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=92,129,39) | 33 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=92,129,39) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=978,1518,420) | 28 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=978,1518,420) | 24 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=92,129,39) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=978,1518,420) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=28,22,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=978,1518,420) | 102 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=28,22,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=978,1518,420) | 36 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=28,22,7) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, France (n=28,22,7) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=28,22,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, France (n=978,1518,420) | 108 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=978,1518,420) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=978,1518,420) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=92,129,39) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=978,1518,420) | 71 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=978,1518,420) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=978,1518,420) | 172 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=978,1518,420) | 70 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=92,129,39) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=978,1518,420) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=978,1518,420) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=92,129,39) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=978,1518,420) | 389 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=978,1518,420) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=978,1518,420) | 64 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=92,129,39) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=978,1518,420) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=92,129,39) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=978,1518,420) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=978,1518,420) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=978,1518,420) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=978,1518,420) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, France (n=28,22,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=978,1518,420) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=28,22,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=978,1518,420) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=978,1518,420) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=978,1518,420) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=978,1518,420) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=978,1518,420) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=978,1518,420) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=28,22,7) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=978,1518,420) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=978,1518,420) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=978,1518,420) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=978,1518,420) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=28,22,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=978,1518,420) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=92,129,39) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=978,1518,420) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=92,129,39) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=92,129,39) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=978,1518,420) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, France (n=92,129,39) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=978,1518,420) | 34 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=92,129,39) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=978,1518,420) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=92,129,39) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=978,1518,420) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=92,129,39) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=978,1518,420) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=92,129,39) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=978,1518,420) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=978,1518,420) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, France (n=978,1518,420) | 24 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=92,129,39) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=978,1518,420) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=92,129,39) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=978,1518,420) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=978,1518,420) | 56 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=92,129,39) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=978,1518,420) | 125 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=92,129,39) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=978,1518,420) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=92,129,39) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=92,129,39) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=978,1518,420) | 2 participants |
Comparison: G4p-value: 0.0637Chi-squared
Comparison: Other genotypesp-value: 0.0474Chi-squared
Comparison: Total genotypesp-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Europe (n=14,22,5) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Middle East (n=92,38,11) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Latin America (n=490,914,296) | 27 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Middle East (n=26,67,21) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Europe (n=92,38,11) | 29 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Asia (n=295,703,239) | 83 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Latin America (n=63,84,20) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Asia (n=92,38,11) | 59 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Europe (n=295,703,239) | 174 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Middle East (n=14,22,5) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Latin America (n=295,703,239) | 21 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Middle East (n=295,703,239) | 17 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Europe (n=26,67,21) | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Middle East (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Latin America (n=14,22,5) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Asia (n=14,22,5) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Europe (n=63,84,20) | 52 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Asia (n=490,914,296) | 155 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Latin America (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Asia (n=63,84,20) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Europe (n=490,914,296) | 275 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Asia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Latin America (n=92,38,11) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Middle East (n=490,914,296) | 33 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Europe (n=92,38,11) | 28 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Latin America (n=26,67,21) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Asia (n=14,22,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Europe (n=14,22,5) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Middle East (n=14,22,5) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Latin America (n=14,22,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Asia (n=490,914,296) | 36 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Europe (n=490,914,296) | 664 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Middle East (n=490,914,296) | 135 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Latin America (n=490,914,296) | 79 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Asia (n=295,703,239) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Europe (n=295,703,239) | 534 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Middle East (n=295,703,239) | 87 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Latin America (n=295,703,239) | 69 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Asia (n=92,38,11) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Middle East (n=26,67,21) | 29 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Middle East (n=92,38,11) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Latin America (n=92,38,11) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Asia (n=63,84,20) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Europe (n=63,84,20) | 61 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Middle East (n=63,84,20) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Latin America (n=63,84,20) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Asia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Europe (n=26,67,21) | 36 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Latin America (n=63,84,20) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Middle East (n=92,38,11) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Europe (n=490,914,296) | 222 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Asia (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Latin America (n=92,38,11) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Asia (n=490,914,296) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Europe (n=26,67,21) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Asia (n=63,84,20) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Latin America (n=14,22,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Asia (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Europe (n=63,84,20) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Middle East (n=14,22,5) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Latin America (n=26,67,21) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Middle East (n=295,703,239) | 30 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Europe (n=295,703,239) | 186 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Middle East (n=63,84,20) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Latin America (n=295,703,239) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Asia (n=295,703,239) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Europe (n=14,22,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Asia (n=92,38,11) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Latin America (n=490,914,296) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Middle East (n=26,67,21) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Europe (n=92,38,11) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Middle East (n=490,914,296) | 43 participants |
Comparison: G1p-value: <0.0001Chi-squared
Comparison: G2p-value: <0.0001Chi-squared
Comparison: G3p-value: 0.5275Chi-squared
Comparison: G4p-value: 0.6593Chi-squared
Comparison: Other genotypesp-value: 0.0372Chi-squared
Comparison: Total genotypesp-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G2, Middle East (n=126,160,37) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G1, Europe (n=500,930,272) | 388 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G1, Middle East (n=500,930,272) | 65 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G1, Latin America (n=500,930,272) | 31 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G2, Asia (n=126,160,37) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G2, Europe (n=126,160,37) | 111 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G1, Asia (n=500,930,272) | 16 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G2, Latin America (n=126,160,37) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G3, Asia (n=232,277,65) | 45 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G3, Europe (n=232,277,65) | 177 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G3, Middle East (n=232,277,65) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G3, Latin America (n=232,277,65) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G4, Asia (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G4, Europe (n=92,129,39) | 37 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G4, Middle East (n=92,129,39) | 53 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G4, Latin America (n=92,129,39) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Other, Asia (n=28,22,7) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Other, Europe (n=28,22,7) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Other, Middle East (n=28,22,7) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Other, Latin America (n=28,22,7) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Total, Asia (n=978,1518,420) | 78 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Total, Europe (n=978,1518,420) | 721 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Total, Middle East (n=978,1518,420) | 138 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Total, Latin America (n=978,1518,420) | 41 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Total, Europe (n=978,1518,420) | 1095 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G1, Asia (n=500,930,272) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G4, Asia (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Other, Asia (n=28,22,7) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G1, Europe (n=500,930,272) | 680 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G3, Middle East (n=232,277,65) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Total, Asia (n=978,1518,420) | 66 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G1, Middle East (n=500,930,272) | 167 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G4, Europe (n=92,129,39) | 64 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Total, Middle East (n=978,1518,420) | 272 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G1, Latin America (n=500,930,272) | 74 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G3, Europe (n=232,277,65) | 200 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Other, Europe (n=28,22,7) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G2, Asia (n=126,160,37) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G4, Middle East (n=92,129,39) | 62 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G3, Latin America (n=232,277,65) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G2, Europe (n=126,160,37) | 144 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G3, Asia (n=232,277,65) | 52 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Total, Latin America (n=978,1518,420) | 85 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G2, Middle East (n=126,160,37) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G4, Latin America (n=92,129,39) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Other, Middle East (n=28,22,7) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G2, Latin America (n=126,160,37) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Other, Latin America (n=28,22,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G2, Latin America (n=126,160,37) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G3, Asia (n=232,277,65) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G3, Europe (n=232,277,65) | 55 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G3, Middle East (n=232,277,65) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Other, Latin America (n=28,22,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G3, Latin America (n=232,277,65) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Total, Middle East (n=978,1518,420) | 75 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G4, Asia (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G4, Europe (n=92,129,39) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Total, Asia (n=978,1518,420) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G4, Middle East (n=92,129,39) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Total, Latin America (n=978,1518,420) | 34 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G4, Latin America (n=92,129,39) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G1, Asia (n=500,930,272) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G1, Europe (n=500,930,272) | 183 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Other, Asia (n=28,22,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G1, Middle East (n=500,930,272) | 57 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Total, Europe (n=978,1518,420) | 303 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G1, Latin America (n=500,930,272) | 32 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G2, Asia (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Other, Europe (n=28,22,7) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G2, Europe (n=126,160,37) | 36 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | G2, Middle East (n=126,160,37) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive | Other, Middle East (n=28,22,7) | 4 participants |
Comparison: G1p-value: <0.0001Chi-squared
Comparison: G2p-value: 0.3572Chi-squared
Comparison: G3p-value: 0.2041Chi-squared
Comparison: G4p-value: 0.0467Chi-squared
Comparison: Other genotypesp-value: 0.0525Chi-squared
Comparison: Total genotypesp-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced | G1 | 295 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced | G2 | 92 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced | G3 | 63 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced | G4 | 26 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced | G4 | 67 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced | G1 | 703 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced | G3 | 84 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced | G2 | 38 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced | G4 | 21 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced | G2 | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced | G3 | 20 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced | G1 | 239 participants |
p-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive | G1 | 500 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive | G2 | 126 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive | G3 | 232 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive | G4 | 92 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive | G4 | 129 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive | G1 | 930 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive | G3 | 277 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive | G2 | 160 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive | G4 | 39 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive | G2 | 37 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive | G3 | 65 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive | G1 | 272 participants |
p-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Experienced | Experienced: IL28B rs8099917 TG | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Experienced | Experienced: IL28B rs8099917 TT | 489 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Experienced | Experienced: IL28B rs8099917 GG | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Experienced | Experienced: IL28B rs8099917 TG | 597 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Experienced | Experienced: IL28B rs8099917 TT | 314 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Experienced | Experienced: IL28B rs8099917 GG | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Experienced | Experienced: IL28B rs8099917 TT | 48 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Experienced | Experienced: IL28B rs8099917 GG | 116 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Experienced | Experienced: IL28B rs8099917 TG | 132 participants |
p-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Naive | Naive: IL28B rs8099917 TG | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Naive | Naive: IL28B rs8099917 TT | 974 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Naive | Naive: IL28B rs8099917 GG | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Naive | Naive: IL28B rs8099917 TG | 965 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Naive | Naive: IL28B rs8099917 TT | 550 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Naive | Naive: IL28B rs8099917 GG | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Naive | Naive: IL28B rs8099917 TT | 74 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Naive | Naive: IL28B rs8099917 GG | 168 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Naive | Naive: IL28B rs8099917 TG | 178 participants |
p-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver inflammation grade (Grade A0, Grade A1, Grade A2, or Grade A3) were obtained from medical records. Liver inflammation grade was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A2 (n=28,7,1) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A1 (n=102,203,60) | 33 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A2 (n=102,203,60) | 48 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A3 (n=102,203,60) | 18 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A0 (n=28,7,1) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A1 (n=28,7,1) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A0 (n=102,203,60) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A3 (n=28,7,1) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A0 (n=11,7,4) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A1 (n=11,7,4) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A2 (n=11,7,4) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A3 (n=11,7,4) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A0 (n=5,29,8) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A1 (n=5,29,8) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A2 (n=5,29,8) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A3 (n=5,29,8) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A0 (n=3,3,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A1 (n=3,3,0) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A2 (n=3,3,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A3 (n=3,3,0) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A0 (n=149,249,73) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A1 (n=149,249,73) | 51 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A2 (n=149,249,73) | 72 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A3 (n=149,249,73) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A1 (n=149,249,73) | 103 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A0 (n=102,203,60) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A0 (n=5,29,8) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A0 (n=3,3,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A1 (n=102,203,60) | 79 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A2 (n=11,7,4) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A0 (n=149,249,73) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A2 (n=102,203,60) | 90 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A1 (n=5,29,8) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A2 (n=149,249,73) | 106 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A3 (n=102,203,60) | 29 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A1 (n=11,7,4) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A1 (n=3,3,0) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A0 (n=28,7,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A2 (n=5,29,8) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A3 (n=11,7,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A1 (n=28,7,1) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A0 (n=11,7,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A3 (n=149,249,73) | 34 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A2 (n=28,7,1) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A3 (n=5,29,8) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A2 (n=3,3,0) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A3 (n=28,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A3 (n=3,3,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A3 (n=28,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A0 (n=11,7,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A1 (n=11,7,4) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A2 (n=11,7,4) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A3 (n=3,3,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A3 (n=11,7,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A2 (n=149,249,73) | 38 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A0 (n=5,29,8) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A1 (n=5,29,8) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A0 (n=149,249,73) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A2 (n=5,29,8) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A3 (n=149,249,73) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A3 (n=5,29,8) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A0 (n=102,203,60) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A1 (n=102,203,60) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A0 (n=3,3,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A2 (n=102,203,60) | 32 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A1 (n=149,249,73) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A3 (n=102,203,60) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A0 (n=28,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A1 (n=3,3,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A1 (n=28,7,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A2 (n=28,7,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A2 (n=3,3,0) | 0 participants |
Comparison: G1p-value: 0.5216Jonckheere-Terpstra Test
Comparison: G2p-value: 0.3419Jonckheere-Terpstra Test
Comparison: G3p-value: 0.7586Jonckheere-Terpstra Test
Comparison: G4p-value: 0.1351Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.2386Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.3921Jonckheere-Terpstra Test
Secondary
Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver inflammation grade (Grade A0, Grade A1, Grade A2, or Grade A3) were obtained from medical records. Liver inflammation grade was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A2 (n=8,4,0) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A1 (n=76,132,46) | 38 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A2 (n=76,132,46) | 27 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A3 (n=76,132,46) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A0 (n=8,4,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A1 (n=8,4,0) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A0 (n=76,132,46) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A3 (n=8,4,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A0 (n=18,14,5) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A1 (n=18,14,5) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A2 (n=18,14,5) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A3 (n=18,14,5) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A0 (n=21,34,8) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A1 (n=21,34,8) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A2 (n=21,34,8) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A3 (n=21,34,8) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A0 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A1 (n=4,0,2) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A2 (n=4,0,2) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A3 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A0 (n=127,184,61) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A1 (n=127,184,61) | 64 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A2 (n=127,184,61) | 46 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A3 (n=127,184,61) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A1 (n=127,184,61) | 84 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A0 (n=76,132,46) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A0 (n=21,34,8) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A0 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A1 (n=76,132,46) | 54 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A2 (n=18,14,5) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A0 (n=127,184,61) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A2 (n=76,132,46) | 57 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A1 (n=21,34,8) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A2 (n=127,184,61) | 67 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A3 (n=76,132,46) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A1 (n=18,14,5) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A1 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A0 (n=8,4,0) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A2 (n=21,34,8) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A3 (n=18,14,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A1 (n=8,4,0) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A0 (n=18,14,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A3 (n=127,184,61) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A2 (n=8,4,0) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A3 (n=21,34,8) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A2 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A3 (n=8,4,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A3 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A3 (n=8,4,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A0 (n=18,14,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A1 (n=18,14,5) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A2 (n=18,14,5) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A3 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A3 (n=18,14,5) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A2 (n=127,184,61) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A0 (n=21,34,8) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A1 (n=21,34,8) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A0 (n=127,184,61) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A2 (n=21,34,8) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A3 (n=127,184,61) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A3 (n=21,34,8) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A0 (n=76,132,46) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A1 (n=76,132,46) | 24 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A0 (n=4,0,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A2 (n=76,132,46) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A1 (n=127,184,61) | 36 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A3 (n=76,132,46) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A0 (n=8,4,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A1 (n=4,0,2) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A1 (n=8,4,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A2 (n=8,4,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A2 (n=4,0,2) | 0 participants |
Comparison: G1p-value: 0.9859Jonckheere-Terpstra Test
Comparison: G2p-value: 0.7055Jonckheere-Terpstra Test
Comparison: G3p-value: 0.092Jonckheere-Terpstra Test
Comparison: G4p-value: 0.0781Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.4795Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.3069Jonckheere-Terpstra Test
Secondary
Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Overall virological response types included sustained virological response (SVR), relapse, and breakthrough. SVR was defined as undetectable HCV RNA level at 24 weeks post-treatment, relapse as an undetectable level at end of treatment with a detectable level at the last post-treatment measurement, and breakthrough as an undetectable level at 1 or more treatment measurements with a detectable level at end of treatment. Undetectable viral loads include those below the LLOD for the assay performed, which may vary from site to site. Response categories were mutually exclusive. Participants with detectable HCV RNA level at 12 or more treatment measurements and who did not meet SVR criteria were considered nonresponders, and those with insufficient treatment response data were recorded as 'none of the above.'
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G1, Relapse | 95 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G3, Nonresponder | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G2, Relapse | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G4, None of above | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G3, Breakthrough | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G2, Breakthrough | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G4, Breakthrough | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G3, SVR | 23 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G2, Nonresponder | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G1, Breakthrough | 20 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G2, None of above | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G1, SVR | 99 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G4, Relapse | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G1, Nonresponder | 43 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G3, Relapse | 19 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G4, SVR | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G1, None of above | 37 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G4, Nonresponder | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G3, None of above | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G2, SVR | 61 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G4, Breakthrough | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G3, Relapse | 24 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G1, SVR | 72 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G1, Relapse | 221 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G1, Breakthrough | 63 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G1, Nonresponder | 253 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G1, None of above | 94 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G2, SVR | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G2, Relapse | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G2, Breakthrough | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G2, Nonresponder | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G2, None of above | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G3, SVR | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G3, Breakthrough | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G3, Nonresponder | 15 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G3, None of above | 21 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G4, SVR | 17 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G4, Relapse | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G4, Nonresponder | 21 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G4, None of above | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G1, SVR | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G3, Nonresponder | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G1, None of above | 45 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G4, None of above | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G3, None of above | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G1, Nonresponder | 92 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G4, Nonresponder | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G4, SVR | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G1, Breakthrough | 24 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G3, Relapse | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G4, Relapse | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G2, Nonresponder | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G1, Relapse | 63 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G2, None of above | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G2, Breakthrough | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G3, SVR | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G2, Relapse | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G4, Breakthrough | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G3, Breakthrough | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype | G2, SVR | 3 participants |
Comparison: G1p-value: <0.0001Jonckheere-Terpstra Test
Comparison: G2p-value: 0.0002Jonckheere-Terpstra Test
Comparison: G3p-value: 0.0394Jonckheere-Terpstra Test
Comparison: G4p-value: 0.0493Jonckheere-Terpstra Test
Secondary
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Virological response types at the end of treatment included undetectable and detectable HCV RNA level. Undetectable viral loads include those below the LLOD for the assay performed, which may vary from site to site.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G1, Undetectable | 194 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G1, Detectable | 62 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G2, Undetectable | 73 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G2, Detectable | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G3, Undetectable | 43 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G3, Detectable | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G4, Undetectable | 16 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G4, Detectable | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G2, Undetectable | 24 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G4, Undetectable | 29 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G2, Detectable | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G3, Undetectable | 48 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G3, Detectable | 21 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G1, Undetectable | 297 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G1, Detectable | 313 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G4, Detectable | 32 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G2, Undetectable | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G1, Detectable | 125 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G1, Undetectable | 79 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G2, Detectable | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G4, Undetectable | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G3, Detectable | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G3, Undetectable | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G4, Detectable | 7 participants |
Comparison: G1p-value: <0.0001Cochran-Armitage Trend Test
Comparison: G2p-value: 0.0421Cochran-Armitage Trend Test
Comparison: G3p-value: 0.7658Cochran-Armitage Trend Test
Comparison: G4p-value: 0.295Cochran-Armitage Trend Test
Secondary
Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Virological response types within the first 12 weeks of treatment included rapid virological response (RVR), complete early virological response (cEVR), and partial early virological response (pEVR). RVR was defined as an undetectable HCV RNA level within the first 4 weeks, cEVR as an undetectable level within the first 12 weeks, and pEVR as a 2-log drop from Baseline to 12 weeks. Undetectable viral loads include those below the lower limit of detection (LLOD) for the assay performed, which may vary from site to site. Response categories were mutually exclusive, meaning participants could only achieve cEVR/pEVR in the absence of RVR. Participants achieving neither RVR nor cEVR/pEVR were recorded as 'none of the above.'
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, RVR | 46 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, cEVR | 117 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, pEVR | 27 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, None of above | 41 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, RVR | 41 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, cEVR | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, pEVR | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, None of above | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, RVR | 20 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, cEVR | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, pEVR | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, None of above | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, RVR | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, cEVR | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, pEVR | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, None of above | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, cEVR | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, pEVR | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, None of above | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, cEVR | 17 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, RVR | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, cEVR | 27 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, None of above | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, pEVR | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, RVR | 37 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, pEVR | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, cEVR | 199 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, None of above | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, pEVR | 147 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, None of above | 184 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, RVR | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, RVR | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, pEVR | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, cEVR | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, RVR | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, pEVR | 62 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, pEVR | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, None of above | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, RVR | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, None of above | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, None of above | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, RVR | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, RVR | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, cEVR | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, cEVR | 44 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, cEVR | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, None of above | 73 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, pEVR | 5 participants |
Comparison: G1p-value: <0.0001Jonckheere-Terpstra Test
Comparison: G2p-value: 0.0012Jonckheere-Terpstra Test
Comparison: G3p-value: 0.1717Jonckheere-Terpstra Test
Comparison: G4p-value: 0.0253Jonckheere-Terpstra Test
Secondary
Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including self-reported ethnic origin, were obtained from medical records and/or participant interview at the Study Visit.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Native American/American Indian | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Caucasian/white | 628 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Black | 31 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Asian/Oriental | 172 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Other | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Black | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Other | 40 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Asian/Oriental | 31 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Native American/American Indian | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Caucasian/white | 651 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Caucasian/white | 101 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Black | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Native American/American Indian | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Other | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced | Asian/Oriental | 5 participants |
p-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including self-reported ethnic origin, were obtained from medical records and/or participant interview at the Study Visit.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Native American/American Indian | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Asian/Oriental | 123 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Caucasian/white | 1402 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Black | 34 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Other | 38 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Asian/Oriental | 53 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Caucasian/white | 1030 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Black | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Native American/American Indian | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Other | 52 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Other | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Native American/American Indian | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Caucasian/white | 150 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Asian/Oriental | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive | Black | 2 participants |
p-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including gender, were obtained from medical records and/or participant interview at the Study Visit.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Experienced | Male | 489 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Experienced | Female | 362 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Experienced | Male | 412 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Experienced | Female | 318 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Experienced | Female | 55 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Experienced | Male | 64 participants |
p-value: 0.4545Cochran-Armitage Trend Test
Secondary
Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. Demographic characteristics, including gender, were obtained from medical records and/or participant interview at the Study Visit.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Naive | Male | 910 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Naive | Female | 688 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Naive | Male | 608 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Naive | Female | 539 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Naive | Male | 90 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Naive | Female | 81 participants |
p-value: 0.042Cochran-Armitage Trend Test
Secondary
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=563,574,100) | 37 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=563,574,100) | 28 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=563,574,100) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=563,574,100) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, France (n=563,574,100) | 80 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=563,574,100) | 33 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=563,574,100) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=563,574,100) | 88 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=563,574,100) | 22 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=563,574,100) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=563,574,100) | 27 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=563,574,100) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=563,574,100) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=563,574,100) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=563,574,100) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=563,574,100) | 23 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=563,574,100) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=563,574,100) | 51 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=563,574,100) | 84 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=563,574,100) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=563,574,100) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=563,574,100) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=563,574,100) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=563,574,100) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=563,574,100) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, France (n=107,27,7) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=107,27,7) | 22 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=107,27,7) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=107,27,7) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=107,27,7) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=107,27,7) | 61 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=107,27,7) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=107,27,7) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=93,65,9) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=93,65,9) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=93,65,9) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, France (n=93,65,9) | 18 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=93,65,9) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=93,65,9) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=93,65,9) | 22 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=93,65,9) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=93,65,9) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=93,65,9) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=93,65,9) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=93,65,9) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=93,65,9) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=93,65,9) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=93,65,9) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=563,574,100) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=93,65,9) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=563,574,100) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=563,574,100) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=563,574,100) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=93,65,9) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=93,65,9) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=563,574,100) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=107,27,7) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, France (n=563,574,100) | 117 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=93,65,9) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=563,574,100) | 29 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=93,65,9) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=563,574,100) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=93,65,9) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=563,574,100) | 98 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=563,574,100) | 33 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=563,574,100) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=107,27,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=563,574,100) | 30 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=107,27,7) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=563,574,100) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=107,27,7) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, France (n=107,27,7) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=563,574,100) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, France (n=93,65,9) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=563,574,100) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=563,574,100) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=563,574,100) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=93,65,9) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=563,574,100) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=107,27,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=93,65,9) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=563,574,100) | 66 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=563,574,100) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=93,65,9) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=563,574,100) | 46 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=93,65,9) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=563,574,100) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=93,65,9) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=563,574,100) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=563,574,100) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=93,65,9) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=563,574,100) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=107,27,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=563,574,100) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=93,65,9) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=563,574,100) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, France (n=107,27,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=93,65,9) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=107,27,7) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=107,27,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=93,65,9) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=107,27,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=93,65,9) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=107,27,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=563,574,100) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=563,574,100) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=563,574,100) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=93,65,9) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, France (n=563,574,100) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=563,574,100) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=563,574,100) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=93,65,9) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=563,574,100) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=563,574,100) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=563,574,100) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=563,574,100) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=563,574,100) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, France (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=563,574,100) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=563,574,100) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=563,574,100) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=563,574,100) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=563,574,100) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=93,65,9) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=563,574,100) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=93,65,9) | 0 participants |
Comparison: G1p-value: <0.0001Chi-squared
Comparison: G2p-value: 0.0048Chi-squared
Comparison: G3p-value: 0.5127Chi-squared
Secondary
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=71,43,0) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=71,43,0) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=71,43,0) | 26 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, France (n=71,43,0) | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=71,43,0) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=71,43,0) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=71,43,0) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=71,43,0) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=71,43,0) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=71,43,0) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=71,43,0) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=17,21,3) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, France (n=17,21,3) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=17,21,3) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=17,21,3) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=17,21,3) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=17,21,3) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=17,21,3) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=17,21,3) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=851,730,119) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=851,730,119) | 45 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=851,730,119) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=851,730,119) | 26 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=851,730,119) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, France (n=851,730,119) | 129 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=851,730,119) | 39 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=851,730,119) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=851,730,119) | 140 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=851,730,119) | 23 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=851,730,119) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=851,730,119) | 40 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=851,730,119) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=851,730,119) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=851,730,119) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=851,730,119) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=851,730,119) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=851,730,119) | 42 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=851,730,119) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=851,730,119) | 51 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=851,730,119) | 149 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=851,730,119) | 47 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=851,730,119) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=851,730,119) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=851,730,119) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=851,730,119) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=851,730,119) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=851,730,119) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=17,21,3) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=851,730,119) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=71,43,0) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=851,730,119) | 34 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=851,730,119) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=71,43,0) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=17,21,3) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=851,730,119) | 66 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=71,43,0) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=851,730,119) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=851,730,119) | 33 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=17,21,3) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=17,21,3) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, France (n=71,43,0) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=851,730,119) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=71,43,0) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=851,730,119) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=71,43,0) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=851,730,119) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=71,43,0) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=851,730,119) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=71,43,0) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=851,730,119) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=851,730,119) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=17,21,3) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=851,730,119) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=17,21,3) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, France (n=17,21,3) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, France (n=851,730,119) | 141 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=851,730,119) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=71,43,0) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=851,730,119) | 33 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=851,730,119) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=851,730,119) | 60 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=851,730,119) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=851,730,119) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=851,730,119) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=851,730,119) | 128 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=851,730,119) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=851,730,119) | 39 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=851,730,119) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=851,730,119) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=851,730,119) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=851,730,119) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, France (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=851,730,119) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=851,730,119) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=851,730,119) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=17,21,3) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=851,730,119) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=851,730,119) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=851,730,119) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=851,730,119) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, France (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=851,730,119) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=851,730,119) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=851,730,119) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=851,730,119) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=851,730,119) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, France (n=851,730,119) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=851,730,119) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=851,730,119) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=851,730,119) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=851,730,119) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=851,730,119) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=851,730,119) | 0 participants |
Comparison: G4p-value: 0.3465Chi-squared
Comparison: Other genotypesp-value: 0.7358Chi-squared
Comparison: Total genotypesp-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=837,747,118) | 110 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=837,747,118) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=837,747,118) | 32 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=837,747,118) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=837,747,118) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=837,747,118) | 62 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, France (n=837,747,118) | 82 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=837,747,118) | 50 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=837,747,118) | 35 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=837,747,118) | 160 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=837,747,118) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=837,747,118) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=837,747,118) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=837,747,118) | 37 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=837,747,118) | 18 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=837,747,118) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=837,747,118) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=837,747,118) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=837,747,118) | 20 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=837,747,118) | 19 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=837,747,118) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=837,747,118) | 97 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=837,747,118) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=837,747,118) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=837,747,118) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=837,747,118) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=837,747,118) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=837,747,118) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=837,747,118) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=837,747,118) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=198,113,12) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=198,113,12) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, France (n=198,113,12) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=198,113,12) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=198,113,12) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=198,113,12) | 128 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=198,113,12) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=198,113,12) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=198,113,12) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=198,113,12) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=198,113,12) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=198,113,12) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=198,113,12) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=198,113,12) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=198,113,12) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=198,113,12) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=198,113,12) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=361,186,27) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=361,186,27) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=361,186,27) | 36 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, France (n=361,186,27) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=361,186,27) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=361,186,27) | 34 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=361,186,27) | 109 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=361,186,27) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=361,186,27) | 22 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=361,186,27) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=361,186,27) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=361,186,27) | 67 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=361,186,27) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=361,186,27) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=361,186,27) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=361,186,27) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=361,186,27) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=361,186,27) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=361,186,27) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=361,186,27) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=361,186,27) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=361,186,27) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=198,113,12) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=361,186,27) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=198,113,12) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, France (n=198,113,12) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=361,186,27) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=361,186,27) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=198,113,12) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=198,113,12) | 91 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=361,186,27) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=361,186,27) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=198,113,12) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=361,186,27) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=198,113,12) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=361,186,27) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=198,113,12) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=361,186,27) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=361,186,27) | 33 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=198,113,12) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=198,113,12) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=361,186,27) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=198,113,12) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=361,186,27) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=837,747,118) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=837,747,118) | 32 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=837,747,118) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=361,186,27) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=837,747,118) | 58 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, France (n=837,747,118) | 53 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=837,747,118) | 45 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=837,747,118) | 29 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=837,747,118) | 139 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=837,747,118) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=837,747,118) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=837,747,118) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=361,186,27) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=837,747,118) | 32 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=837,747,118) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=837,747,118) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, France (n=361,186,27) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=837,747,118) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=837,747,118) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=837,747,118) | 31 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=361,186,27) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=837,747,118) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=837,747,118) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=361,186,27) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=837,747,118) | 102 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=361,186,27) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=837,747,118) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=837,747,118) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=837,747,118) | 115 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=837,747,118) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=837,747,118) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=361,186,27) | 43 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=837,747,118) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=837,747,118) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=837,747,118) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=361,186,27) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=837,747,118) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=837,747,118) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=361,186,27) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=837,747,118) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=837,747,118) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=837,747,118) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=361,186,27) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, France (n=361,186,27) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=837,747,118) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=361,186,27) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=837,747,118) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, France (n=198,113,12) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=837,747,118) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=837,747,118) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=361,186,27) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=837,747,118) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=198,113,12) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=837,747,118) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=837,747,118) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, France (n=837,747,118) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=361,186,27) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=837,747,118) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=198,113,12) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=837,747,118) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=837,747,118) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=198,113,12) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=837,747,118) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=837,747,118) | 28 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=837,747,118) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=837,747,118) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=837,747,118) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=837,747,118) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=361,186,27) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=837,747,118) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=837,747,118) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=837,747,118) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=837,747,118) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=361,186,27) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=837,747,118) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=361,186,27) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=837,747,118) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=837,747,118) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=837,747,118) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=837,747,118) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=837,747,118) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=198,113,12) | 0 participants |
Comparison: G1p-value: 0.0381Chi-squared
Comparison: G2p-value: 0.6852Chi-squared
Comparison: G3p-value: 0.1185Chi-squared
Secondary
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=165,85,10) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=165,85,10) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=165,85,10) | 41 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, France (n=165,85,10) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=165,85,10) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=165,85,10) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=165,85,10) | 47 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=165,85,10) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=165,85,10) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=165,85,10) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=165,85,10) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=165,85,10) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=165,85,10) | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=165,85,10) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=165,85,10) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=37,16,4) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, France (n=37,16,4) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=37,16,4) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=37,16,4) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=37,16,4) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=37,16,4) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=37,16,4) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=37,16,4) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=37,16,4) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=37,16,4) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=37,16,4) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=1598,1147,171) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=1598,1147,171) | 61 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=1598,1147,171) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=1598,1147,171) | 41 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=1598,1147,171) | 105 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, France (n=1598,1147,171) | 111 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=1598,1147,171) | 70 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=1598,1147,171) | 80 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=1598,1147,171) | 445 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=1598,1147,171) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=1598,1147,171) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=1598,1147,171) | 33 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=1598,1147,171) | 68 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=1598,1147,171) | 30 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=1598,1147,171) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=1598,1147,171) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=1598,1147,171) | 76 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=1598,1147,171) | 23 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=1598,1147,171) | 27 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=1598,1147,171) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=1598,1147,171) | 99 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=1598,1147,171) | 28 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=1598,1147,171) | 149 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=1598,1147,171) | 19 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=1598,1147,171) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=1598,1147,171) | 21 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=1598,1147,171) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=1598,1147,171) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=1598,1147,171) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=1598,1147,171) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=1598,1147,171) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=165,85,10) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=1598,1147,171) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=165,85,10) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=1598,1147,171) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=1598,1147,171) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=37,16,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=1598,1147,171) | 102 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=165,85,10) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=1598,1147,171) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=1598,1147,171) | 45 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=165,85,10) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=37,16,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, France (n=165,85,10) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=1598,1147,171) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=1598,1147,171) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=165,85,10) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=1598,1147,171) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=1598,1147,171) | 37 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=165,85,10) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=165,85,10) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=1598,1147,171) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=1598,1147,171) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=165,85,10) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=1598,1147,171) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=37,16,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=1598,1147,171) | 85 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=37,16,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=1598,1147,171) | 31 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=37,16,4) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, France (n=37,16,4) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, France (n=1598,1147,171) | 75 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=1598,1147,171) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=1598,1147,171) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=165,85,10) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=1598,1147,171) | 55 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=1598,1147,171) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=1598,1147,171) | 133 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=1598,1147,171) | 56 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=165,85,10) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=1598,1147,171) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=1598,1147,171) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=165,85,10) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=1598,1147,171) | 295 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=1598,1147,171) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=165,85,10) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=1598,1147,171) | 44 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=165,85,10) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=1598,1147,171) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=165,85,10) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=37,16,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=1598,1147,171) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=1598,1147,171) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=1598,1147,171) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=1598,1147,171) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, France (n=37,16,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=1598,1147,171) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=37,16,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=1598,1147,171) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=1598,1147,171) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=1598,1147,171) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=1598,1147,171) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=1598,1147,171) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=1598,1147,171) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=37,16,4) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=1598,1147,171) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=1598,1147,171) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=1598,1147,171) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=1598,1147,171) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=1598,1147,171) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=1598,1147,171) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=165,85,10) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=1598,1147,171) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, France (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=1598,1147,171) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=165,85,10) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=1598,1147,171) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=165,85,10) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=1598,1147,171) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=1598,1147,171) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=165,85,10) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=1598,1147,171) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=1598,1147,171) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, France (n=1598,1147,171) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=1598,1147,171) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=1598,1147,171) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=1598,1147,171) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=1598,1147,171) | 51 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=1598,1147,171) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=165,85,10) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=1598,1147,171) | 0 participants |
Comparison: G4p-value: 0.2611Chi-squared
Comparison: Other genotypesp-value: 0.6059Chi-squared
Comparison: Total genotypesp-value: 0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Middle East (n=107,27,7) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Europe (n=563,574,100) | 378 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Middle East (n=563,574,100) | 59 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Latin America (n=563,574,100) | 39 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Asia (n=107,27,7) | 61 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Europe (n=107,27,7) | 40 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Asia (n=563,574,100) | 87 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Latin America (n=107,27,7) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Asia (n=93,65,9) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Europe (n=93,65,9) | 76 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Middle East (n=93,65,9) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Latin America (n=93,65,9) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Asia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Europe (n=71,43,0) | 41 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Middle East (n=71,43,0) | 29 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Latin America (n=71,43,0) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Asia (n=17,21,3) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Europe (n=17,21,3) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Middle East (n=17,21,3) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Latin America (n=17,21,3) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Asia (n=851,730,119) | 164 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Europe (n=851,730,119) | 541 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Middle East (n=851,730,119) | 97 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Latin America (n=851,730,119) | 49 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Europe (n=851,730,119) | 537 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Asia (n=563,574,100) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Asia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Asia (n=17,21,3) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Europe (n=563,574,100) | 442 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Middle East (n=93,65,9) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Asia (n=851,730,119) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Middle East (n=563,574,100) | 62 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Europe (n=71,43,0) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Middle East (n=851,730,119) | 98 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Latin America (n=563,574,100) | 61 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Europe (n=93,65,9) | 47 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Europe (n=17,21,3) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Asia (n=107,27,7) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Middle East (n=71,43,0) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Latin America (n=93,65,9) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Europe (n=107,27,7) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Asia (n=93,65,9) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Latin America (n=851,730,119) | 68 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Middle East (n=107,27,7) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Latin America (n=71,43,0) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Middle East (n=17,21,3) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Latin America (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Latin America (n=17,21,3) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Latin America (n=107,27,7) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Asia (n=93,65,9) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Europe (n=93,65,9) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Middle East (n=93,65,9) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Latin America (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Latin America (n=93,65,9) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Middle East (n=851,730,119) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Asia (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Europe (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Asia (n=851,730,119) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Middle East (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Latin America (n=851,730,119) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Latin America (n=71,43,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Asia (n=563,574,100) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Europe (n=563,574,100) | 74 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Asia (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Middle East (n=563,574,100) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Europe (n=851,730,119) | 83 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Latin America (n=563,574,100) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Asia (n=107,27,7) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Europe (n=17,21,3) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Europe (n=107,27,7) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Middle East (n=107,27,7) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Middle East (n=17,21,3) | 3 participants |
Comparison: G1p-value: <0.0001Chi-squared
Comparison: G2p-value: 0.0001Chi-squared
Comparison: G3p-value: 0.482Chi-squared
Comparison: G4p-value: 0.8668Chi-squared
Comparison: Other genotypesp-value: 0.2032Chi-squared
Comparison: Total genotypesp-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G2, Middle East (n=198,113,12) | 15 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G1, Europe (n=837,747,118) | 632 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G1, Middle East (n=837,747,118) | 138 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G1, Latin America (n=837,747,118) | 48 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G2, Asia (n=198,113,12) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G2, Europe (n=198,113,12) | 174 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G1, Asia (n=837,747,118) | 19 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G2, Latin America (n=198,113,12) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G3, Asia (n=361,186,27) | 67 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G3, Europe (n=361,186,27) | 275 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G3, Middle East (n=361,186,27) | 17 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G3, Latin America (n=361,186,27) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G4, Asia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G4, Europe (n=165,85,10) | 77 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G4, Middle East (n=165,85,10) | 85 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G4, Latin America (n=165,85,10) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Other, Asia (n=37,16,4) | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Other, Europe (n=37,16,4) | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Other, Middle East (n=37,16,4) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Other, Latin America (n=37,16,4) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Total, Asia (n=1598,1147,171) | 104 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Total, Europe (n=1598,1147,171) | 1169 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Total, Middle East (n=1598,1147,171) | 264 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Total, Latin America (n=1598,1147,171) | 61 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Total, Europe (n=1598,1147,171) | 834 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G1, Asia (n=837,747,118) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G4, Asia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Other, Asia (n=37,16,4) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G1, Europe (n=837,747,118) | 543 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G3, Middle East (n=361,186,27) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Total, Asia (n=1598,1147,171) | 43 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G1, Middle East (n=837,747,118) | 130 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G4, Europe (n=165,85,10) | 46 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Total, Middle East (n=1598,1147,171) | 193 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G1, Latin America (n=837,747,118) | 68 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G3, Europe (n=361,186,27) | 135 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Other, Europe (n=37,16,4) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G2, Asia (n=198,113,12) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G4, Middle East (n=165,85,10) | 37 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G3, Latin America (n=361,186,27) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G2, Europe (n=198,113,12) | 106 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G3, Asia (n=361,186,27) | 33 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Total, Latin America (n=1598,1147,171) | 77 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G2, Middle East (n=198,113,12) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G4, Latin America (n=165,85,10) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Other, Middle East (n=37,16,4) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G2, Latin America (n=198,113,12) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Other, Latin America (n=37,16,4) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G2, Latin America (n=198,113,12) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G3, Asia (n=361,186,27) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G3, Europe (n=361,186,27) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G3, Middle East (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Other, Latin America (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G3, Latin America (n=361,186,27) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Total, Middle East (n=1598,1147,171) | 28 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G4, Asia (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G4, Europe (n=165,85,10) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Total, Asia (n=1598,1147,171) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G4, Middle East (n=165,85,10) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Total, Latin America (n=1598,1147,171) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G4, Latin America (n=165,85,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G1, Asia (n=837,747,118) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G1, Europe (n=837,747,118) | 76 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Other, Asia (n=37,16,4) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G1, Middle East (n=837,747,118) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Total, Europe (n=1598,1147,171) | 116 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G1, Latin America (n=837,747,118) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G2, Asia (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Other, Europe (n=37,16,4) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G2, Europe (n=198,113,12) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | G2, Middle East (n=198,113,12) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive | Other, Middle East (n=37,16,4) | 2 participants |
Comparison: G1p-value: <0.0001Chi-squared
Comparison: G2p-value: 0.3857Chi-squared
Comparison: G3p-value: 0.2356Chi-squared
Comparison: G4p-value: 0.7993Chi-squared
Comparison: Other genotypesp-value: 0.2164Chi-squared
Comparison: Total genotypesp-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced | G1 | 563 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced | G2 | 107 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced | G3 | 93 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced | G4 | 71 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced | G4 | 43 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced | G1 | 574 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced | G3 | 65 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced | G2 | 27 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced | G4 | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced | G2 | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced | G3 | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced | G1 | 100 participants |
p-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype was obtained from medical records.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive | G1 | 837 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive | G2 | 198 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive | G3 | 361 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive | G4 | 165 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive | G4 | 85 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive | G1 | 747 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive | G3 | 186 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive | G2 | 113 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive | G4 | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive | G2 | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive | G3 | 27 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive | G1 | 118 participants |
p-value: <0.0001Chi-squared
Secondary
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver inflammation grade (Grade A0, Grade A1, Grade A2, or Grade A3) were obtained from medical records. Liver inflammation grade was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A2 (n=30,5,1) | 16 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A1 (n=160,177,28) | 52 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A2 (n=160,177,28) | 77 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A3 (n=160,177,28) | 27 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A0 (n=30,5,1) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A1 (n=30,5,1) | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A0 (n=160,177,28) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A3 (n=30,5,1) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A0 (n=14,6,2) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A1 (n=14,6,2) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A2 (n=14,6,2) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A3 (n=14,6,2) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A0 (n=28,14,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A1 (n=28,14,0) | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A2 (n=28,14,0) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A3 (n=28,14,0) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A0 (n=3,3,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A1 (n=3,3,0) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A2 (n=3,3,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A3 (n=3,3,0) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A0 (n=235,205,31) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A1 (n=235,205,31) | 85 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A2 (n=235,205,31) | 110 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A3 (n=235,205,31) | 35 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A1 (n=235,205,31) | 85 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A0 (n=160,177,28) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A0 (n=28,14,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A0 (n=3,3,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A1 (n=160,177,28) | 70 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A2 (n=14,6,2) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A0 (n=235,205,31) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A2 (n=160,177,28) | 79 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A1 (n=28,14,0) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A2 (n=235,205,31) | 90 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A3 (n=160,177,28) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A1 (n=14,6,2) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A1 (n=3,3,0) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A0 (n=30,5,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A2 (n=28,14,0) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A3 (n=14,6,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A1 (n=30,5,1) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A0 (n=14,6,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A3 (n=235,205,31) | 24 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A2 (n=30,5,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A3 (n=28,14,0) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A2 (n=3,3,0) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A3 (n=30,5,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A3 (n=3,3,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A3 (n=30,5,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A0 (n=14,6,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A1 (n=14,6,2) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A2 (n=14,6,2) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A3 (n=3,3,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G3, Grade A3 (n=14,6,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A2 (n=235,205,31) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A0 (n=28,14,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A1 (n=28,14,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A0 (n=235,205,31) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A2 (n=28,14,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A3 (n=235,205,31) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G4, Grade A3 (n=28,14,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A0 (n=160,177,28) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A1 (n=160,177,28) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A0 (n=3,3,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A2 (n=160,177,28) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Total, Grade A1 (n=235,205,31) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G1, Grade A3 (n=160,177,28) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A0 (n=30,5,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A1 (n=3,3,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A1 (n=30,5,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | G2, Grade A2 (n=30,5,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced | Other, Grade A2 (n=3,3,0) | 0 participants |
Comparison: G1p-value: 0.2416Jonckheere-Terpstra Test
Comparison: G2p-value: 0.2671Jonckheere-Terpstra Test
Comparison: G3p-value: 0.4619Jonckheere-Terpstra Test
Comparison: G4p-value: 0.8364Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.2386Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.2887Jonckheere-Terpstra Test
Secondary
Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and liver inflammation grade (Grade A0, Grade A1, Grade A2, or Grade A3) were obtained from medical records. Liver inflammation grade was based upon previous biopsy using the METAVIR scoring system and captured prior to treatment, if applicable.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A2 (n=11,1,0) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A1 (n=127,109,18) | 63 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A2 (n=127,109,18) | 46 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A3 (n=127,109,18) | 17 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A0 (n=11,1,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A1 (n=11,1,0) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A0 (n=127,109,18) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A3 (n=11,1,0) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A0 (n=22,13,2) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A1 (n=22,13,2) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A2 (n=22,13,2) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A3 (n=22,13,2) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A0 (n=43,19,1) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A1 (n=43,19,1) | 29 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A2 (n=43,19,1) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A3 (n=43,19,1) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A0 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A1 (n=4,1,1) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A2 (n=4,1,1) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A3 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A0 (n=207,143,22) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A1 (n=207,143,22) | 109 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A2 (n=207,143,22) | 69 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A3 (n=207,143,22) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A1 (n=207,143,22) | 64 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A0 (n=127,109,18) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A0 (n=43,19,1) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A0 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A1 (n=127,109,18) | 45 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A2 (n=22,13,2) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A0 (n=207,143,22) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A2 (n=127,109,18) | 45 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A1 (n=43,19,1) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A2 (n=207,143,22) | 52 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A3 (n=127,109,18) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A1 (n=22,13,2) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A1 (n=4,1,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A0 (n=11,1,0) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A2 (n=43,19,1) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A3 (n=22,13,2) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A1 (n=11,1,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A0 (n=22,13,2) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A3 (n=207,143,22) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A2 (n=11,1,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A3 (n=43,19,1) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A2 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A3 (n=11,1,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A3 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A3 (n=11,1,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A0 (n=22,13,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A1 (n=22,13,2) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A2 (n=22,13,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A3 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G3, Grade A3 (n=22,13,2) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A2 (n=207,143,22) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A0 (n=43,19,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A1 (n=43,19,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A0 (n=207,143,22) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A2 (n=43,19,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A3 (n=207,143,22) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G4, Grade A3 (n=43,19,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A0 (n=127,109,18) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A1 (n=127,109,18) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A0 (n=4,1,1) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A2 (n=127,109,18) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Total, Grade A1 (n=207,143,22) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G1, Grade A3 (n=127,109,18) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A0 (n=11,1,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A1 (n=4,1,1) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A1 (n=11,1,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | G2, Grade A2 (n=11,1,0) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive | Other, Grade A2 (n=4,1,1) | 0 participants |
Comparison: G1p-value: 0.8537Jonckheere-Terpstra Test
Comparison: G2p-value: 0.0763Jonckheere-Terpstra Test
Comparison: G3p-value: 0.2432Jonckheere-Terpstra Test
Comparison: G4p-value: 0.4247Jonckheere-Terpstra Test
Comparison: Other genotypesp-value: 0.4884Jonckheere-Terpstra Test
Comparison: Total genotypesp-value: 0.6119Jonckheere-Terpstra Test
Secondary
Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Overall virological response types included SVR, relapse, and breakthrough. SVR was defined as undetectable HCV RNA level at 24 weeks post-treatment, relapse as an undetectable level at end of treatment with a detectable level at the last post-treatment measurement, and breakthrough as an undetectable level at 1 or more treatment measurements with a detectable level at end of treatment. Undetectable viral loads include those below the LLOD for the assay performed, which may vary from site to site. Response categories were mutually exclusive. Participants with detectable HCV RNA level at 12 or more treatment measurements and who did not meet SVR criteria were considered nonresponders, and those with insufficient treatment response data were recorded as 'none of the above.'
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G3, None of above | 19 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G2, Breakthrough | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G1, SVR | 133 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G3, Nonresponder | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G2, Nonresponder | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G1, Nonresponder | 115 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G3, Breakthrough | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G2, None of above | 17 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G4, None of above | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G3, Relapse | 27 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G3, SVR | 29 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G4, Breakthrough | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G1, None of above | 78 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G4, Nonresponder | 16 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G4, Relapse | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G2, SVR | 64 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G1, Breakthrough | 42 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G4, SVR | 21 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G2, Relapse | 20 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G1, Relapse | 194 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G4, Breakthrough | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G1, SVR | 46 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G1, Relapse | 168 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G1, Breakthrough | 49 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G1, Nonresponder | 232 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G1, None of above | 79 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G2, SVR | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G2, Relapse | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G2, Breakthrough | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G2, Nonresponder | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G2, None of above | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G3, SVR | 15 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G3, Relapse | 21 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G3, Breakthrough | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G3, Nonresponder | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G3, None of above | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G4, SVR | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G4, Relapse | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G4, Nonresponder | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G4, None of above | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G1, Relapse | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G3, Nonresponder | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G2, Relapse | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G4, None of above | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G3, None of above | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G2, SVR | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G4, Nonresponder | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G4, SVR | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G1, None of above | 19 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G1, SVR | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G4, Relapse | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G1, Nonresponder | 41 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G3, SVR | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G2, None of above | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G1, Breakthrough | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G3, Relapse | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G2, Nonresponder | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G4, Breakthrough | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G3, Breakthrough | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype | G2, Breakthrough | 0 participants |
Comparison: G1p-value: <0.0001Jonckheere-Terpstra Test
Comparison: G2p-value: 0.0196Jonckheere-Terpstra Test
Comparison: G3p-value: 0.3268Jonckheere-Terpstra Test
Comparison: G4p-value: 0.1667Jonckheere-Terpstra Test
Secondary
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Virological response types at the end of treatment included undetectable and detectable HCV RNA level. Undetectable viral loads include those below the LLOD for the assay performed, which may vary from site to site.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G4, Detectable | 27 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G1, Undetectable | 326 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G2, Detectable | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G4, Undetectable | 37 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G1, Detectable | 161 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G3, Undetectable | 59 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G2, Undetectable | 82 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G3, Detectable | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G2, Undetectable | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G1, Undetectable | 222 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G4, Undetectable | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G4, Detectable | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G3, Undetectable | 39 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G3, Detectable | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G2, Detectable | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G1, Detectable | 279 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G4, Detectable | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G1, Undetectable | 22 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G1, Detectable | 60 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G2, Undetectable | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G2, Detectable | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G3, Undetectable | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G3, Detectable | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype | G4, Undetectable | 0 participants |
Comparison: G1p-value: <0.0001Cochran-Armitage Trend Test
Comparison: G2p-value: 0.0827Cochran-Armitage Trend Test
Comparison: G3p-value: 0.7817Cochran-Armitage Trend Test
Comparison: G4p-value: 0.1986Cochran-Armitage Trend Test
Secondary
Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype
Participants underwent blood sampling at the Study Visit to determine IL28B genotype. HCV RNA genotype and virological response to prior treatment were obtained from medical records. Virological response types within the first 12 weeks of treatment included RVR, cEVR, and pEVR. RVR was defined as an undetectable HCV RNA level within the first 4 weeks, cEVR as an undetectable level within the first 12 weeks, and pEVR as a 2-log drop from Baseline to 12 weeks. Undetectable viral loads include those below the LLOD for the assay performed, which may vary from site to site. Response categories were mutually exclusive, meaning participants could only achieve cEVR/pEVR in the absence of RVR. Participants achieving neither RVR nor cEVR/pEVR were recorded as 'none of the above.'
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, RVR | 50 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, cEVR | 205 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, pEVR | 88 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, None of above | 92 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, RVR | 59 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, cEVR | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, pEVR | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, None of above | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, RVR | 23 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, cEVR | 23 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, pEVR | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, None of above | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, RVR | 17 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, cEVR | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, pEVR | 11 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, None of above | 15 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, cEVR | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, pEVR | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, None of above | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, cEVR | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, RVR | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, cEVR | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, None of above | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, pEVR | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, RVR | 23 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, pEVR | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, cEVR | 140 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, None of above | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, pEVR | 128 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, None of above | 170 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, RVR | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, RVR | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, pEVR | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, cEVR | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, RVR | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, pEVR | 20 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, pEVR | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, None of above | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, RVR | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, None of above | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, None of above | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G2, RVR | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, RVR | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, cEVR | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, cEVR | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G3, cEVR | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G1, None of above | 36 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype | G4, pEVR | 0 participants |
Comparison: G1p-value: <0.0001Jonckheere-Terpstra Test
Comparison: G2p-value: 0.033Jonckheere-Terpstra Test
Comparison: G3p-value: 0.1595Jonckheere-Terpstra Test
Comparison: G4p-value: 0.0412Jonckheere-Terpstra Test
Secondary
Number of Participants With Inosine Triphosphatase (ITPA) Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine ITPA genotype.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With Inosine Triphosphatase (ITPA) Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Naive | Naive: ITPA rs1127354 Cysteine-Alanine (CA) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With Inosine Triphosphatase (ITPA) Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Naive | Naive: ITPA rs1127354 AA | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With Inosine Triphosphatase (ITPA) Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Naive | Naive: ITPA rs1127354 CC | 36 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With Inosine Triphosphatase (ITPA) Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Naive | Naive: ITPA rs1127354 Cysteine-Alanine (CA) | 34 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With Inosine Triphosphatase (ITPA) Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Naive | Naive: ITPA rs1127354 AA | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With Inosine Triphosphatase (ITPA) Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Naive | Naive: ITPA rs1127354 CC | 457 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With Inosine Triphosphatase (ITPA) Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Naive | Naive: ITPA rs1127354 AA | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With Inosine Triphosphatase (ITPA) Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Naive | Naive: ITPA rs1127354 CC | 2035 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With Inosine Triphosphatase (ITPA) Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Naive | Naive: ITPA rs1127354 Cysteine-Alanine (CA) | 343 participants |
p-value: <0.0001Chi-squared
Secondary
Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records. Past medication use was obtained from medical records and/or participant interview at the Study Visit. Participants with a history of erythropoietin use during prior treatment for CHC were recorded as 'yes' for this finding.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G1, Yes (n=10,162,1016) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G1, No (n=10,162,1016) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G2, Yes (n=3,30,105) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G2, No (n=3,30,105) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G3, Yes (n=2,24,137) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G3, No (n=2,24,137) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G4, Yes (n=0,5,106) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G4, No (n=0,5,106) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Other, Yes (n=0,4,24) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Other, No (n=0,4,24) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Total, Yes (n=15,225,1388) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Total, No (n=15,225,1388) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Total, No (n=15,225,1388) | 212 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G1, Yes (n=10,162,1016) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G4, Yes (n=0,5,106) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Other, Yes (n=0,4,24) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G1, No (n=10,162,1016) | 154 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G3, No (n=2,24,137) | 24 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Total, Yes (n=15,225,1388) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G2, Yes (n=3,30,105) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G4, No (n=0,5,106) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G3, Yes (n=2,24,137) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G2, No (n=3,30,105) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Other, No (n=0,4,24) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G2, No (n=3,30,105) | 91 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G3, Yes (n=2,24,137) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Other, No (n=0,4,24) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G3, No (n=2,24,137) | 133 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G4, Yes (n=0,5,106) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G4, No (n=0,5,106) | 88 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Total, Yes (n=15,225,1388) | 142 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G1, Yes (n=10,162,1016) | 103 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G1, No (n=10,162,1016) | 913 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Other, Yes (n=0,4,24) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G2, Yes (n=3,30,105) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Total, No (n=15,225,1388) | 1246 participants |
Comparison: G1p-value: 0.0634Cochran-Armitage Trend Test
Comparison: G2p-value: 0.7176Cochran-Armitage Trend Test
Comparison: G3p-value: 0.3944Cochran-Armitage Trend Test
Comparison: G4p-value: 0.861Cochran-Armitage Trend Test
Comparison: Other genotypesp-value: 0.4543Cochran-Armitage Trend Test
Comparison: Total genotypesp-value: 0.0406Cochran-Armitage Trend Test
Secondary
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=10,169,1057) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, France (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=10,169,1057) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=10,169,1057) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=10,169,1057) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=3,30,108) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, France (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, France (n=10,169,1057) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=3,30,108) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=3,30,10) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=10,169,1057) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=10,169,1057) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=2,26,139) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=10,169,1057) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, France (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=10,169,1057) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=2,26,139) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=10,169,1057) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=10,169,1057) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=10,169,1057) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=2,26,139) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=10,169,1057) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=2,26,139) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=10,169,1057) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=2,26,139) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=10,169,1057) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=10,169,1057) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=10,169,1057) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=10,169,1057) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=10,169,1057) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, France (n=3,30,108) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=10,169,1057) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=3,30,108) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=3,30,108) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=10,169,1057) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=10,169,1057) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=10,169,1057) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=10,169,1057) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, France (n=10,169,1057) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=3,30,108) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=10,169,1057) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=10,169,1057) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=10,169,1057) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=3,30,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=10,169,1057) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=10,169,1057) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=10,169,1057) | 52 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=10,169,1057) | 25 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=10,169,1057) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=10,169,1057) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, France (n=10,169,1057) | 185 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=10,169,1057) | 60 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=10,169,1057) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=10,169,1057) | 177 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=10,169,1057) | 50 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=10,169,1057) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=10,169,1057) | 47 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=10,169,1057) | 24 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=10,169,1057) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=10,169,1057) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=10,169,1057) | 29 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=10,169,1057) | 31 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=10,169,1057) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=10,169,1057) | 114 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=10,169,1057) | 64 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=10,169,1057) | 82 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=10,169,1057) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=10,169,1057) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=10,169,1057) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=10,169,1057) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=10,169,1057) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, France (n=3,30,108) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=3,30,108) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=3,30,108) | 32 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=3,30,108) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=3,30,108) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=3,30,108) | 45 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=3,30,108) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=3,30,10) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=3,30,108) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=2,26,139) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=2,26,139) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=2,26,139) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, France (n=2,26,139) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=2,26,139) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=2,26,139) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=2,26,139) | 29 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=2,26,139) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=2,26,139) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=2,26,139) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=2,26,139) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=2,26,139) | 0 participants |
Comparison: G1p-value: 0.1236Chi-squared
Comparison: G2p-value: 0.0119Chi-squared
Comparison: G3p-value: 0.7472Chi-squared
Secondary
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, France (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, France (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=15,235,1449) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=15,235,1449) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, France (n=15,235,1449) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=15,235,1449) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=15,235,1449) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=15,235,1449) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=15,235,1449) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=15,235,1449) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=15,235,1449) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=0,5,109) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=15,235,1449) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=15,235,1449) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=0,5,36) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=15,235,1449) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=0,5,109) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=15,235,1449) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=15,235,1449) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, France (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=15,235,1449) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=15,235,1449) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=15,235,1449) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=0,5,109) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=15,235,1449) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=15,235,1449) | 48 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=15,235,1449) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=0,5,36) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, France (n=0,5,36) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, France (n=15,235,1449) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=15,235,1449) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=15,235,1449) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=15,235,1449) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=15,235,1449) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=15,235,1449) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=15,235,1449) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=15,235,1449) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=15,235,1449) | 34 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=15,235,1449) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=15,235,1449) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=15,235,1449) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=0,5,36) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=15,235,1449) | 52 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=15,235,1449) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=15,235,1449) | 24 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, France (n=0,5,36) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=15,235,1449) | 62 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=0,5,36) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=15,235,1449) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=15,235,1449) | 28 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=0,5,36) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=0,5,36) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=15,235,1449) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=0,5,36) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=0,5,36) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=15,235,1449) | 25 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=15,235,1449) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=0,5,36) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=0,5,36) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=15,235,1449) | 31 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=15,235,1449) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=15,235,1449) | 56 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=15,235,1449) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=0,5,36) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=15,235,1449) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=0,5,109) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=0,5,109) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=15,235,1449) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=0,5,109) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=0,5,109) | 38 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=15,235,1449) | 72 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, France (n=0,5,109) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=15,235,1449) | 114 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=0,5,109) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=0,5,109) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=15,235,1449) | 30 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=0,5,109) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=15,235,1449) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=15,235,1449) | 39 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=0,5,109) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=15,235,1449) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=15,235,1449) | 112 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, France (n=15,235,1449) | 255 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=0,5,109) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=15,235,1449) | 69 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=0,5,109) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=15,235,1449) | 35 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=15,235,1449) | 106 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=15,235,1449) | 252 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=0,5,109) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=15,235,1449) | 0 participants |
Comparison: G4p-value: 0.9734Chi-squared
Comparison: Other genotypesp-value: 0.8303Chi-squared
Comparison: Total genotypesp-value: 0.0006Chi-squared
Secondary
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=9,212,1481) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, France (n=9,212,1481) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=9,212,1481) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=9,212,1481) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=9,212,1481) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=9,212,1481) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=9,212,1481) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, France (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, France (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=1,83,490) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=9,212,1481) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=9,212,1481) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=0,45,278) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=1,83,490) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=9,212,1481) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=0,45,278) | 29 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, France (n=9,212,1481) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=0,45,278) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=9,212,1481) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=9,212,1481) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=1,83,490) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=1,83,490) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=9,212,1481) | 45 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=9,212,1481) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=1,83,490) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=9,212,1481) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=9,212,1481) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=0,45,278) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=1,83,490) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=9,212,1481) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=0,45,278) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=1,83,490) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=0,45,278) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, France (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=9,212,1481) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=0,45,278) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, France (n=1,83,490) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=9,212,1481) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=9,212,1481) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=9,212,1481) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=1,83,490) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=0,45,278) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=1,83,490) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=9,212,1481) | 32 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=0,45,278) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=1,83,490) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=9,212,1481) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=1,83,490) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=9,212,1481) | 28 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=9,212,1481) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=9,212,1481) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=1,83,490) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=9,212,1481) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=1,83,490) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=0,45,278) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=1,83,490) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=9,212,1481) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=0,45,278) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=0,45,278) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=9,212,1481) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=1,83,490) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=9,212,1481) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=0,45,278) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=1,83,490) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=0,45,278) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=1,83,490) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, France (n=0,45,278) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=0,45,278) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=0,45,278) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=1,83,490) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=0,45,278) | 199 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=0,45,278) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=1,83,490) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=0,45,278) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=1,83,490) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=0,45,278) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=1,83,490) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=0,45,278) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=1,83,490) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=0,45,278) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=1,83,490) | 88 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=1,83,490) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=0,45,278) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=0,45,278) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=1,83,490) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=0,45,278) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=1,83,490) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=0,45,278) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=0,45,278) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=1,83,490) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=9,212,1481) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=9,212,1481) | 57 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=1,83,490) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=9,212,1481) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=9,212,1481) | 114 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=1,83,490) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, France (n=9,212,1481) | 121 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=1,83,490) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=9,212,1481) | 86 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=9,212,1481) | 62 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=9,212,1481) | 280 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=1,83,490) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=9,212,1481) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=9,212,1481) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=9,212,1481) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=9,212,1481) | 59 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=9,212,1481) | 25 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=1,83,490) | 52 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=9,212,1481) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=9,212,1481) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=9,212,1481) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, France (n=1,83,490) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=9,212,1481) | 58 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=9,212,1481) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=9,212,1481) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=1,83,490) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=9,212,1481) | 183 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=9,212,1481) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=9,212,1481) | 214 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=1,83,490) | 50 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=9,212,1481) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=1,83,490) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=9,212,1481) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=9,212,1481) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=1,83,490) | 136 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=9,212,1481) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=9,212,1481) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=9,212,1481) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=1,83,490) | 0 participants |
Comparison: G1p-value: <0.0001Chi-squared
Comparison: G2p-value: 0.1947Chi-squared
Comparison: G3p-value: 0.0226Chi-squared
Secondary
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, France (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, France (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=1,7,49) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, France (n=11,377,2528) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=11,377,2528) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=11,377,2528) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=11,377,2528) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=11,377,2528) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=11,377,2528) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=11,377,2528) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=11,377,2528) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=11,377,2528) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=11,377,2528) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=0,30,230) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=11,377,2528) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=11,377,2528) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=11,377,2528) | 32 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=0,30,230) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=11,377,2528) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=11,377,2528) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=1,7,49) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, France (n=0,30,230) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=11,377,2528) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=11,377,2528) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=0,30,230) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=11,377,2528) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=11,377,2528) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=0,30,230) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=0,30,230) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=11,377,2528) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=11,377,2528) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=0,30,230) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=11,377,2528) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=1,7,49) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=11,377,2528) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=11,377,2528) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=1,7,49) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, France (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=1,7,49) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, France (n=11,377,2528) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=11,377,2528) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=11,377,2528) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=11,377,2528) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=11,377,2528) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=11,377,2528) | 38 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=11,377,2528) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=0,30,230) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=11,377,2528) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=1,7,49) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=11,377,2528) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=0,30,230) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=11,377,2528) | 109 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=11,377,2528) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=0,30,230) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=11,377,2528) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=0,30,230) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=11,377,2528) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=0,30,230) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=1,7,49) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=11,377,2528) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=11,377,2528) | 33 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=11,377,2528) | 54 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, France (n=1,7,49) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=1,7,49) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=11,377,2528) | 97 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=1,7,49) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=11,377,2528) | 37 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=11,377,2528) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=11,377,2528) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=1,7,49) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=11,377,2528) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=1,7,49) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=11,377,2528) | 97 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=11,377,2528) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=1,7,49) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=1,7,49) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=11,377,2528) | 60 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=11,377,2528) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=11,377,2528) | 36 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=11,377,2528) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=1,7,49) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=11,377,2528) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=0,30,230) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=0,30,230) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=11,377,2528) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=0,30,230) | 54 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=0,30,230) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=11,377,2528) | 93 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, France (n=0,30,230) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=11,377,2528) | 185 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=0,30,230) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=0,30,230) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=11,377,2528) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=0,30,230) | 63 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=11,377,2528) | 28 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=0,30,230) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=11,377,2528) | 54 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=0,30,230) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=11,377,2528) | 176 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=11,377,2528) | 24 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, France (n=11,377,2528) | 171 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=0,30,230) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=11,377,2528) | 112 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=0,30,230) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=11,377,2528) | 128 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=11,377,2528) | 263 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=0,30,230) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=11,377,2528) | 680 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=0,30,230) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=11,377,2528) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=0,30,230) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=0,30,230) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=11,377,2528) | 7 participants |
Comparison: G4p-value: 0.1158Chi-squared
Comparison: Other genotypesp-value: 0.3675Chi-squared
Comparison: Total genotypesp-value: 0.0948Chi-squared
Secondary
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Middle East (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Europe (n=10,169,1057) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Middle East (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Latin America (n=10,169,1057) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Asia (n=3,30,108) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Europe (n=3,30,108) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Asia (n=10,169,1057) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Latin America (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Asia (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Europe (n=2,26,139) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Middle East (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Latin America (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Asia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Europe (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Middle East (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Latin America (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Asia (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Europe (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Middle East (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Latin America (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Asia (n=15,235,1449) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Europe (n=15,235,1449) | 10 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Middle East (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Latin America (n=15,235,1449) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Europe (n=15,235,1449) | 149 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Asia (n=10,169,1057) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Asia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Asia (n=0,5,36) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Europe (n=10,169,1057) | 117 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Middle East (n=2,26,139) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Asia (n=15,235,1449) | 53 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Middle East (n=10,169,1057) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Europe (n=0,5,109) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Middle East (n=15,235,1449) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Latin America (n=10,169,1057) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Europe (n=2,26,139) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Europe (n=0,5,36) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Asia (n=3,30,108) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Middle East (n=0,5,109) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Latin America (n=2,26,139) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Europe (n=3,30,108) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Asia (n=2,26,139) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Latin America (n=15,235,1449) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Middle East (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Latin America (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Middle East (n=0,5,36) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Latin America (n=3,30,108) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Latin America (n=0,5,36) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Latin America (n=3,30,108) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Asia (n=2,26,139) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Europe (n=2,26,139) | 107 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Middle East (n=2,26,139) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Latin America (n=0,5,36) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Latin America (n=2,26,139) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Middle East (n=15,235,1449) | 189 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Asia (n=0,5,109) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Europe (n=0,5,109) | 62 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Asia (n=15,235,1449) | 137 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Middle East (n=0,5,109) | 45 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Latin America (n=15,235,1449) | 122 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Latin America (n=0,5,109) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Asia (n=10,169,1057) | 67 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Europe (n=10,169,1057) | 768 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Asia (n=0,5,36) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Middle East (n=10,169,1057) | 118 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Europe (n=15,235,1449) | 1001 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Latin America (n=10,169,1057) | 104 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Asia (n=3,30,108) | 45 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Europe (n=0,5,36) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Europe (n=3,30,108) | 53 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Middle East (n=3,30,108) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Middle East (n=0,5,36) | 18 participants |
Comparison: G1p-value: 0.0003Chi-squared
Comparison: G2p-value: 0.1637Chi-squared
Comparison: G3p-value: 0.8579Chi-squared
Comparison: G4p-value: 0.6935Chi-squared
Comparison: Other genotypesp-value: 0.8124Chi-squared
Comparison: Total genotypesp-value: <0.0001Chi-squared
Secondary
Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Total, Asia (n=11,377,2528) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Other, Asia (n=1,7,49) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Other, Europe (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Other, Middle East (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G2, Middle East (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Other, Latin America (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G2, Europe (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G1, Middle East (n=9,212,1481) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Total, Europe (n=11,377,2528) | 8 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G2, Latin America (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Total, Middle East (n=11,377,2528) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Total, Latin America (n=11,377,2528) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G3, Asia (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G1, Asia (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G3, Europe (n=1,83,490) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G1, Latin America (n=9,212,1481) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G3, Middle East (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G3, Latin America (n=1,83,490) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G1, Europe (n=9,212,1481) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G4, Asia (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G2, Asia (n=0,45,278) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G4, Europe (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G4, Middle East (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G4, Latin America (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G1, Middle East (n=9,212,1481) | 32 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G2, Asia (n=0,45,278) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Other, Asia (n=1,7,49) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G2, Europe (n=0,45,278) | 37 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G3, Asia (n=1,83,490) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G1, Asia (n=9,212,1481) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G4, Latin America (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Other, Middle East (n=1,7,49) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G4, Asia (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G3, Europe (n=1,83,490) | 62 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Other, Latin America (n=1,7,49) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G2, Middle East (n=0,45,278) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G4, Middle East (n=0,30,230) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Total, Asia (n=11,377,2528) | 30 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G1, Europe (n=9,212,1481) | 167 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G3, Middle East (n=1,83,490) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Total, Europe (n=11,377,2528) | 284 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G1, Latin America (n=9,212,1481) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G4, Europe (n=0,30,230) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Total, Middle East (n=11,377,2528) | 55 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G2, Latin America (n=0,45,278) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G3, Latin America (n=1,83,490) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Total, Latin America (n=11,377,2528) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Other, Europe (n=1,7,49) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Total, Latin America (n=11,377,2528) | 152 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G1, Asia (n=9,212,1481) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G1, Europe (n=9,212,1481) | 1077 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G1, Middle East (n=9,212,1481) | 255 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G1, Latin America (n=9,212,1481) | 132 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G2, Asia (n=0,45,278) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G2, Europe (n=0,45,278) | 254 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G2, Middle East (n=0,45,278) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G2, Latin America (n=0,45,278) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G3, Asia (n=1,83,490) | 88 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G3, Europe (n=1,83,490) | 369 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G3, Middle East (n=1,83,490) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G3, Latin America (n=1,83,490) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G4, Asia (n=0,30,230) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G4, Europe (n=0,30,230) | 112 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G4, Middle East (n=0,30,230) | 113 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | G4, Latin America (n=0,30,230) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Other, Asia (n=1,7,49) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Other, Europe (n=1,7,49) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Other, Middle East (n=1,7,49) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Other, Latin America (n=1,7,49) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Total, Asia (n=11,377,2528) | 121 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Total, Europe (n=11,377,2528) | 1827 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive | Total, Middle East (n=11,377,2528) | 428 participants |
Comparison: G1p-value: 0.0018Chi-squared
Comparison: G2p-value: 0.0425Chi-squared
Comparison: G3p-value: 0.9829Chi-squared
Comparison: G4p-value: 0.67Chi-squared
Comparison: Other genotypesp-value: 0.7672Chi-squared
Comparison: Total genotypesp-value: 0.0067Chi-squared
Secondary
Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype and hematology data were obtained from medical records. Participants with a history of a hemoglobin level less than 10 grams per deciliter (g/dL) or a drop of more than 3 g/dL at any time during prior treatment for CHC were recorded as 'yes' for this finding.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G1, Yes (n=9,133,810) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G1, No (n=9,133,810) | 7 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G2, Yes (n=3,27,89) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G2, No (n=3,27,89) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G3, Yes (n=2,20,105) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G3, No (n=2,20,105) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G4, Yes (n=0,2,85) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G4, No (n=0,2,85) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Other, Yes (n=0,3,23) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Other, No (n=0,3,23) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Total, Yes (n=14,185,1112) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Total, No (n=14,185,1112) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Total, No (n=14,185,1112) | 139 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G1, Yes (n=9,133,810) | 35 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G4, Yes (n=0,2,85) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Other, Yes (n=0,3,23) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G1, No (n=9,133,810) | 98 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G3, No (n=2,20,105) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Total, Yes (n=14,185,1112) | 46 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G2, Yes (n=3,27,89) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G4, No (n=0,2,85) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G3, Yes (n=2,20,105) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G2, No (n=3,27,89) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Other, No (n=0,3,23) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G2, No (n=3,27,89) | 47 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G3, Yes (n=2,20,105) | 33 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Other, No (n=0,3,23) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G3, No (n=2,20,105) | 72 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G4, Yes (n=0,2,85) | 36 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G4, No (n=0,2,85) | 49 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Total, Yes (n=14,185,1112) | 448 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G1, Yes (n=9,133,810) | 322 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G1, No (n=9,133,810) | 488 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Other, Yes (n=0,3,23) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G2, Yes (n=3,27,89) | 42 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Total, No (n=14,185,1112) | 664 participants |
Comparison: G1p-value: 0.0021Cochran-Armitage Trend Test
Comparison: G2p-value: 0.5319Cochran-Armitage Trend Test
Comparison: G3p-value: 0.0114Cochran-Armitage Trend Test
Comparison: G4p-value: 0.2293Cochran-Armitage Trend Test
Comparison: Other genotypesp-value: 0.2857Cochran-Armitage Trend Test
Comparison: Total genotypesp-value: 0.0001Cochran-Armitage Trend Test
Secondary
Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records. Past medication use was obtained from medical records and/or participant interview at the Study Visit. Participants with a history of erythropoietin use during prior treatment for CHC were recorded as 'yes' for this finding.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G1, Yes (n=14,206,969) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G1, No (n=14,206,969) | 12 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G2, Yes (n=0,9,128) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G2, No (n=0,9,128) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G3, Yes (n=2,17,144) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G3, No (n=2,17,144) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G4, Yes (n=1,20,90) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G4, No (n=1,20,90) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Other, Yes (n=0,5,23) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Other, No (n=0,5,23) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Total, Yes (n=17,257,1354) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Total, No (n=17,257,1354) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Total, No (n=17,257,1354) | 236 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G1, Yes (n=14,206,969) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G4, Yes (n=1,20,90) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Other, Yes (n=0,5,23) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G1, No (n=14,206,969) | 187 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G3, No (n=2,17,144) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Total, Yes (n=17,257,1354) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G2, Yes (n=0,9,128) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G4, No (n=1,20,90) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G3, Yes (n=2,17,144) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G2, No (n=0,9,128) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Other, No (n=0,5,23) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G2, No (n=0,9,128) | 111 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G3, Yes (n=2,17,144) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Other, No (n=0,5,23) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G3, No (n=2,17,144) | 140 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G4, Yes (n=1,20,90) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G4, No (n=1,20,90) | 73 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Total, Yes (n=17,257,1354) | 132 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G1, Yes (n=14,206,969) | 91 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G1, No (n=14,206,969) | 878 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Other, Yes (n=0,5,23) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | G2, Yes (n=0,9,128) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype | Total, No (n=17,257,1354) | 1222 participants |
Comparison: G1p-value: 0.8234Cochran-Armitage Trend Test
Comparison: G2p-value: 0.2427Cochran-Armitage Trend Test
Comparison: G3p-value: 0.4805Cochran-Armitage Trend Test
Comparison: G4p-value: 0.2901Cochran-Armitage Trend Test
Comparison: Other genotypesp-value: 0.3927Cochran-Armitage Trend Test
Comparison: Total genotypesp-value: 0.5769Cochran-Armitage Trend Test
Secondary
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3])
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, France (n=14,214,1009) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=14,214,1009) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=14,214,1009) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=14,214,1009) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=14,214,1009) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=14,214,1009) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, France (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=1,9,130) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, France (n=2,18,147) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=2,18,147) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=14,214,1009) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=2,18,147) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=14,214,1009) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=14,214,1009) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=2,18,147) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=2,18,147) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=1,9,130) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, France (n=14,214,1009) | 49 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=14,214,1009) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=14,214,1009) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=14,214,1009) | 41 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=14,214,1009) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=14,214,1009) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=14,214,1009) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=14,214,1009) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, France (n=1,9,130) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, France (n=2,18,147) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=14,214,1009) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=14,214,1009) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=2,18,147) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=14,214,1009) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=1,9,130) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=2,18,147) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=14,214,1009) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=2,18,147) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=14,214,1009) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=14,214,1009) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=2,18,147) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=14,214,1009) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=2,18,147) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=14,214,1009) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=1,9,130) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=1,9,130) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=14,214,1009) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=2,18,147) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=14,214,1009) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=2,18,147) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, France (n=1,9,130) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=2,18,147) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=1,9,130) | 35 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=1,9,130) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=2,18,147) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=1,9,130) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=2,18,147) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=1,9,130) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=2,18,147) | 25 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=2,18,147) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=1,9,130) | 67 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=1,9,130) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=2,18,147) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=2,18,147) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=1,9,130) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=14,214,1009) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=14,214,1009) | 54 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=2,18,147) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=14,214,1009) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=14,214,1009) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=14,214,1009) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=2,18,147) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, France (n=14,214,1009) | 157 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=14,214,1009) | 50 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=14,214,1009) | 24 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=2,18,147) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=14,214,1009) | 158 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=14,214,1009) | 51 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=14,214,1009) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=14,214,1009) | 48 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=14,214,1009) | 24 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=2,18,147) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=14,214,1009) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=14,214,1009) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, France (n=2,18,147) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=14,214,1009) | 28 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=14,214,1009) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=14,214,1009) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=2,18,147) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=14,214,1009) | 107 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=14,214,1009) | 92 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=14,214,1009) | 78 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=2,18,147) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=14,214,1009) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=2,18,147) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=14,214,1009) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=2,18,147) | 29 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=14,214,1009) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=14,214,1009) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=2,18,147) | 0 participants |
Comparison: G1p-value: 0.0097Chi-squared
Comparison: G2p-value: <0.0001Chi-squared
Comparison: G3p-value: 0.9778Chi-squared
Secondary
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total])
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, France (n=18,270,1411) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=1,22,91) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=18,270,1411) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=18,270,1411) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=18,270,1411) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=18,270,1411) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=18,270,1411) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=18,270,1411) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=18,270,1411) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, France (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, France (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=18,270,1411) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=0,7,34) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=18,270,1411) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=18,270,1411) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=0,7,34) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=18,270,1411) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, France (n=18,270,1411) | 62 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=1,22,91) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=18,270,1411) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=18,270,1411) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=18,270,1411) | 49 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=1,22,91) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=18,270,1411) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, France (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=18,270,1411) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=18,270,1411) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=1,22,91) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=18,270,1411) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=18,270,1411) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=18,270,1411) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=1,22,91) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=18,270,1411) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=18,270,1411) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=18,270,1411) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, France (n=1,22,91) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=1,22,91) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=18,270,1411) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=18,270,1411) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=1,22,91) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=18,270,1411) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=0,7,34) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=18,270,1411) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=18,270,1411) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=1,22,91) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=18,270,1411) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=1,22,91) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=1,22,91) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=1,22,91) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=1,22,91) | 36 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, France (n=1,22,91) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=1,22,91) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=1,22,91) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=1,22,91) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=1,22,91) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=1,22,91) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=1,22,91) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=0,7,34) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, France (n=0,7,34) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=0,7,34) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=0,7,34) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=0,7,34) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=0,7,34) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=0,7,34) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=0,7,34) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=0,7,34) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=18,270,1411) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=18,270,1411) | 72 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=18,270,1411) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=18,270,1411) | 37 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=18,270,1411) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, France (n=18,270,1411) | 217 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=18,270,1411) | 58 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=18,270,1411) | 33 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=18,270,1411) | 235 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=18,270,1411) | 53 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=18,270,1411) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=18,270,1411) | 67 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=18,270,1411) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=18,270,1411) | 29 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=18,270,1411) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=18,270,1411) | 31 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=18,270,1411) | 30 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=18,270,1411) | 50 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=18,270,1411) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=18,270,1411) | 107 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=18,270,1411) | 163 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=18,270,1411) | 101 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=18,270,1411) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=18,270,1411) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=18,270,1411) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=18,270,1411) | 6 participants |
Comparison: G4p-value: 0.0151Chi-squared
Comparison: Other genotypesp-value: 0.1052Chi-squared
Comparison: Total genotypesp-value: 0.0007Chi-squared
Secondary
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3])
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G1, G2, G3) is continued onto the subsequent table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=17,300,1385) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=17,300,1385) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=17,300,1385) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, France (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=6,56,261) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=9,81,484) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, France (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=9,81,484) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=9,81,484) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=9,81,484) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=9,81,484) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=17,300,1385) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, France (n=17,300,1385) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=17,300,1385) | 6 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=17,300,1385) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=17,300,1385) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=9,81,484) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=17,300,1385) | 43 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=17,300,1385) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, France (n=9,81,484) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=17,300,1385) | 41 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=17,300,1385) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=17,300,1385) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=9,81,484) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=17,300,1385) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=17,300,1385) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=17,300,1385) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=9,81,484) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=17,300,1385) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=17,300,1385) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, France (n=17,300,1385) | 29 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=9,81,484) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=17,300,1385) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=17,300,1385) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=17,300,1385) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=6,56,261) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=17,300,1385) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=6,56,261) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=9,81,484) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=17,300,1385) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=9,81,484) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=6,56,261) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=9,81,484) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=9,81,484) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, France (n=6,56,261) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=9,81,484) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=6,56,261) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=17,300,1385) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=6,56,261) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=9,81,484) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=9,81,484) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=6,56,261) | 40 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=9,81,484) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=17,300,1385) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=17,300,1385) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=9,81,484) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=6,56,261) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=9,81,484) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=6,56,261) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=6,56,261) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=17,300,1385) | 57 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=17,300,1385) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=9,81,484) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=6,56,261) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=17,300,1385) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Portugal (n=6,56,261) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Qatar (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Romania (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Venezuela (n=9,81,484) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Taiwan (n=6,56,261) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lithuania (n=17,300,1385) | 55 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Turkey (n=6,56,261) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Slovakia (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Argentina (n=17,300,1385) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Serbia (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Sweden (n=6,56,261) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Switzerland (n=6,56,261) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Belgium (n=17,300,1385) | 59 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Syria (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, United Arab Emirates (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Venezuela (n=6,56,261) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Chile (n=17,300,1385) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Argentina (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Macedonia (n=17,300,1385) | 25 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Belgium (n=9,81,484) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Chile (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Egypt (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Egypt (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Estonia (n=9,81,484) | 46 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, France (n=9,81,484) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Estonia (n=17,300,1385) | 104 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Germany (n=9,81,484) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Greece (n=9,81,484) | 50 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Italy (n=9,81,484) | 137 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, France (n=17,300,1385) | 110 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Kuwait (n=9,81,484) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Mexico (n=17,300,1385) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Latvia (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lebanon (n=9,81,484) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Germany (n=17,300,1385) | 87 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Lithuania (n=9,81,484) | 22 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Peru (n=17,300,1385) | 58 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Macedonia (n=9,81,484) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Mexico (n=9,81,484) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Greece (n=17,300,1385) | 61 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Oman (n=9,81,484) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Pakistan (n=9,81,484) | 98 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Peru (n=9,81,484) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Italy (n=17,300,1385) | 264 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Portugal (n=9,81,484) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Oman (n=17,300,1385) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Qatar (n=17,300,1385) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Romania (n=17,300,1385) | 167 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Qatar (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Taiwan (n=17,300,1385) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Turkey (n=17,300,1385) | 202 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Slovakia (n=17,300,1385) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Romania (n=9,81,484) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Serbia (n=17,300,1385) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Kuwait (n=17,300,1385) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Sweden (n=17,300,1385) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Switzerland (n=17,300,1385) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Taiwan (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Syria (n=17,300,1385) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Portugal (n=17,300,1385) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, United Arab Emirates (n=17,300,1385) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Venezuela (n=17,300,1385) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Turkey (n=9,81,484) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Argentina (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Belgium (n=6,56,261) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Chile (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Slovakia (n=9,81,484) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Egypt (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Latvia (n=17,300,1385) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Estonia (n=6,56,261) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, France (n=6,56,261) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Serbia (n=9,81,484) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Germany (n=6,56,261) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Greece (n=6,56,261) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Italy (n=6,56,261) | 182 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Sweden (n=9,81,484) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Kuwait (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Latvia (n=6,56,261) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lebanon (n=6,56,261) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Switzerland (n=9,81,484) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Lithuania (n=6,56,261) | 13 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Lebanon (n=17,300,1385) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Macedonia (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Mexico (n=6,56,261) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, Syria (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Oman (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G1, Pakistan (n=17,300,1385) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Pakistan (n=6,56,261) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G2, Peru (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]) | G3, United Arab Emirates (n=9,81,484) | 2 participants |
Comparison: G1p-value: 0.0065Chi-squared
Comparison: G2p-value: 0.9999Chi-squared
Comparison: G3p-value: 0.3472Chi-squared
Secondary
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total])
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and country of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category. The table below (G4, Other, Total) is a continuation of the preceding table; thus, the overall number of participants analyzed reflects the total number analyzed among all genotypes (G1, G2, G3, G4, and Other).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=3,51,206) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, France (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=3,51,206) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=1,3,53) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, France (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=36,491,2389) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=36,491,2389) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=36,491,2389) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, France (n=36,491,2389) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=36,491,2389) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=36,491,2389) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=36,491,2389) | 16 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=36,491,2389) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=36,491,2389) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=36,491,2389) | 5 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=36,491,2389) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=36,491,2389) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=36,491,2389) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=3,51,206) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=36,491,2389) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=3,51,206) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=36,491,2389) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=36,491,2389) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=3,51,206) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=36,491,2389) | 43 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=36,491,2389) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=36,491,2389) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, France (n=3,51,206) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=36,491,2389) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=3,51,206) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=36,491,2389) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=3,51,206) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=36,491,2389) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=36,491,2389) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=3,51,206) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=36,491,2389) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=36,491,2389) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=3,51,206) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=36,491,2389) | 33 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=1,3,53) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=36,491,2389) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=1,3,53) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, France (n=1,3,53) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, France (n=36,491,2389) | 39 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=36,491,2389) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=36,491,2389) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=3,51,206) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=36,491,2389) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=36,491,2389) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=36,491,2389) | 45 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=36,491,2389) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=36,491,2389) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=36,491,2389) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=36,491,2389) | 138 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=36,491,2389) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=3,51,206) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=3,51,206) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=36,491,2389) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Venezuela (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Argentina (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Belgium (n=1,3,53) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Latvia (n=36,491,2389) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Chile (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Slovakia (n=36,491,2389) | 25 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Egypt (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Estonia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lebanon (n=36,491,2389) | 42 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, France (n=1,3,53) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Germany (n=1,3,53) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Greece (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Lithuania (n=36,491,2389) | 90 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Italy (n=1,3,53) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Kuwait (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Latvia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Macedonia (n=36,491,2389) | 36 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lebanon (n=1,3,53) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Serbia (n=36,491,2389) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Lithuania (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Macedonia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Mexico (n=36,491,2389) | 23 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Mexico (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Oman (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Pakistan (n=1,3,53) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Oman (n=36,491,2389) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Peru (n=1,3,53) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Portugal (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Qatar (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Pakistan (n=36,491,2389) | 111 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Romania (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Sweden (n=36,491,2389) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Taiwan (n=1,3,53) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Turkey (n=1,3,53) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Peru (n=36,491,2389) | 61 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Slovakia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, United Arab Emirates (n=36,491,2389) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Serbia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Sweden (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Portugal (n=36,491,2389) | 27 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Switzerland (n=1,3,53) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Syria (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, United Arab Emirates (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Qatar (n=36,491,2389) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Other, Venezuela (n=1,3,53) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Switzerland (n=36,491,2389) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Argentina (n=3,51,206) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Belgium (n=3,51,206) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Argentina (n=36,491,2389) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Chile (n=3,51,206) | 47 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Egypt (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Estonia (n=3,51,206) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Belgium (n=36,491,2389) | 93 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, France (n=3,51,206) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Romania (n=36,491,2389) | 169 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Germany (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Greece (n=3,51,206) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Chile (n=36,491,2389) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Italy (n=3,51,206) | 51 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Venezuela (n=36,491,2389) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Kuwait (n=3,51,206) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Latvia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Egypt (n=36,491,2389) | 47 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lebanon (n=3,51,206) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Lithuania (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Macedonia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Estonia (n=36,491,2389) | 160 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Mexico (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Taiwan (n=36,491,2389) | 34 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Oman (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Pakistan (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, France (n=36,491,2389) | 154 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Peru (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Portugal (n=3,51,206) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Qatar (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Germany (n=36,491,2389) | 112 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Romania (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Taiwan (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Turkey (n=3,51,206) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Greece (n=36,491,2389) | 126 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Slovakia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Turkey (n=36,491,2389) | 257 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Serbia (n=3,51,206) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Sweden (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Italy (n=36,491,2389) | 637 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Switzerland (n=3,51,206) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Syria (n=36,491,2389) | 17 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, Syria (n=3,51,206) | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | G4, United Arab Emirates (n=3,51,206) | 10 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]) | Total, Kuwait (n=36,491,2389) | 9 participants |
Comparison: G4p-value: 0.2564Chi-squared
Comparison: Other genotypesp-value: 0.7361Chi-squared
Comparison: Total genotypesp-value: <0.0001Chi-squared
Secondary
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Middle East (n=1,9,130) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Europe (n=14,214,1009) | 13 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Middle East (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Latin America (n=14,214,1009) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Asia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Europe (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Asia (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Latin America (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Asia (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Europe (n=2,18,147) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Middle East (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Latin America (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Asia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Europe (n=1,22,91) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Middle East (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Latin America (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Asia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Europe (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Middle East (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Latin America (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Asia (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Europe (n=18,270,1411) | 16 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Middle East (n=18,270,1411) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Latin America (n=18,270,1411) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Europe (n=18,270,1411) | 218 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Asia (n=14,214,1009) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Asia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Asia (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Europe (n=14,214,1009) | 175 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Middle East (n=2,18,147) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Asia (n=18,270,1411) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Middle East (n=14,214,1009) | 21 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Europe (n=1,22,91) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Middle East (n=18,270,1411) | 32 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Latin America (n=14,214,1009) | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Europe (n=2,18,147) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Europe (n=0,7,34) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Asia (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Middle East (n=1,22,91) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Latin America (n=2,18,147) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Europe (n=1,9,130) | 8 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Asia (n=2,18,147) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Latin America (n=18,270,1411) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Middle East (n=1,9,130) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Latin America (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Middle East (n=0,7,34) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Latin America (n=1,9,130) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Latin America (n=0,7,34) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Latin America (n=1,9,130) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Asia (n=2,18,147) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Europe (n=2,18,147) | 110 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Middle East (n=2,18,147) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Latin America (n=0,7,34) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G3, Latin America (n=2,18,147) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Middle East (n=18,270,1411) | 178 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Asia (n=1,22,91) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Europe (n=1,22,91) | 47 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Asia (n=18,270,1411) | 194 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Middle East (n=1,22,91) | 42 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Latin America (n=18,270,1411) | 112 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G4, Latin America (n=1,22,91) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Asia (n=14,214,1009) | 96 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Europe (n=14,214,1009) | 706 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Asia (n=0,7,34) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Middle East (n=14,214,1009) | 113 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Total, Europe (n=18,270,1411) | 927 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G1, Latin America (n=14,214,1009) | 94 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Asia (n=1,9,130) | 67 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Europe (n=0,7,34) | 9 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Europe (n=1,9,130) | 55 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | G2, Middle East (n=1,9,130) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced | Other, Middle East (n=0,7,34) | 17 participants |
Comparison: G1p-value: <0.0001Chi-squared
Comparison: G2p-value: <0.0001Chi-squared
Comparison: G3p-value: 0.4423Chi-squared
Comparison: G4p-value: 0.3824Chi-squared
Comparison: Other genotypesp-value: 0.5246Chi-squared
Comparison: Total genotypesp-value: <0.0001Chi-squared
Secondary
Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype was obtained from medical records, and geographic region of study site was documented during intake/enrollment.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Naive); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Total, Asia (n=36,491,2389) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Other, Europe (n=1,3,53) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Other, Middle East (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G2, Middle East (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Other, Latin America (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Other, Asia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G1, Middle East (n=17,300,1385) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Total, Europe (n=36,491,2389) | 30 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G2, Latin America (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Total, Middle East (n=36,491,2389) | 4 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Total, Latin America (n=36,491,2389) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G3, Asia (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G1, Asia (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G3, Europe (n=9,81,484) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G1, Latin America (n=17,300,1385) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G3, Middle East (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G3, Latin America (n=9,81,484) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G1, Europe (n=17,300,1385) | 14 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G4, Asia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G2, Asia (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G4, Europe (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G4, Middle East (n=3,51,206) | 3 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G4, Latin America (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G2, Europe (n=6,56,261) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G1, Middle East (n=17,300,1385) | 50 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Other, Asia (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G2, Europe (n=6,56,261) | 51 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G3, Latin America (n=9,81,484) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Other, Europe (n=1,3,53) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G1, Asia (n=17,300,1385) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G3, Asia (n=9,81,484) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Other, Middle East (n=1,3,53) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G2, Asia (n=6,56,261) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G4, Latin America (n=3,51,206) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Other, Latin America (n=1,3,53) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G2, Middle East (n=6,56,261) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G3, Europe (n=9,81,484) | 69 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Total, Asia (n=36,491,2389) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G4, Middle East (n=3,51,206) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G1, Europe (n=17,300,1385) | 230 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Total, Europe (n=36,491,2389) | 385 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G3, Middle East (n=9,81,484) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G1, Latin America (n=17,300,1385) | 20 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Total, Middle East (n=36,491,2389) | 74 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G2, Latin America (n=6,56,261) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G4, Europe (n=3,51,206) | 33 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Total, Latin America (n=36,491,2389) | 25 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G4, Asia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Total, Latin America (n=36,491,2389) | 133 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G1, Asia (n=17,300,1385) | 25 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G1, Europe (n=17,300,1385) | 1007 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G1, Middle East (n=17,300,1385) | 238 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G1, Latin America (n=17,300,1385) | 115 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G2, Asia (n=6,56,261) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G2, Europe (n=6,56,261) | 234 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G2, Middle East (n=6,56,261) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G2, Latin America (n=6,56,261) | 5 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G3, Asia (n=9,81,484) | 98 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G3, Europe (n=9,81,484) | 354 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G3, Middle East (n=9,81,484) | 26 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G3, Latin America (n=9,81,484) | 6 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G4, Asia (n=3,51,206) | 0 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G4, Europe (n=3,51,206) | 95 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G4, Middle East (n=3,51,206) | 108 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | G4, Latin America (n=3,51,206) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Other, Asia (n=1,3,53) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Other, Europe (n=1,3,53) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Other, Middle East (n=1,3,53) | 19 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Other, Latin America (n=1,3,53) | 4 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Total, Asia (n=36,491,2389) | 145 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Total, Europe (n=36,491,2389) | 1704 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive | Total, Middle East (n=36,491,2389) | 407 participants |
Comparison: G1p-value: 0.1834Chi-squared
Comparison: G2p-value: 0.8543Chi-squared
Comparison: G3p-value: 0.1485Chi-squared
Comparison: G4p-value: 0.026Chi-squared
Comparison: Other genotypesp-value: 0.5317Chi-squared
Comparison: Total genotypesp-value: 0.0005Chi-squared
Secondary
Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype
Participants underwent blood sampling at the Study Visit to determine ITPA genotype. HCV RNA genotype and hematology data were obtained from medical records. Participants with a history of a hemoglobin level less than 10 g/dL or a drop of more than 3 g/dL at any time during prior treatment for CHC were recorded as 'yes' for this finding.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced); n = number of participants analyzed within each HCV RNA genotype category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G1, Yes (n=10,159,783) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G1, No (n=10,159,783) | 9 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G2, Yes (n=0,8,110) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G2, No (n=0,8,110) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G3, Yes (n=2,14,111) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G3, No (n=2,14,111) | 2 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G4, Yes (n=1,19,67) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G4, No (n=1,19,67) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Other, Yes (n=0,5,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Other, No (n=0,5,21) | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Total, Yes (n=13,205,1092) | 1 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Total, No (n=13,205,1092) | 12 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Total, No (n=13,205,1092) | 147 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G1, Yes (n=10,159,783) | 49 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G4, Yes (n=1,19,67) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Other, Yes (n=0,5,21) | 2 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G1, No (n=10,159,783) | 110 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G3, No (n=2,14,111) | 11 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Total, Yes (n=13,205,1092) | 58 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G2, Yes (n=0,8,110) | 1 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G4, No (n=1,19,67) | 16 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G3, Yes (n=2,14,111) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G2, No (n=0,8,110) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Other, No (n=0,5,21) | 3 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G2, No (n=0,8,110) | 58 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G3, Yes (n=2,14,111) | 31 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Other, No (n=0,5,21) | 7 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G3, No (n=2,14,111) | 80 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G4, Yes (n=1,19,67) | 33 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G4, No (n=1,19,67) | 34 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Total, Yes (n=13,205,1092) | 439 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G1, Yes (n=10,159,783) | 309 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G1, No (n=10,159,783) | 474 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Other, Yes (n=0,5,21) | 14 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | G2, Yes (n=0,8,110) | 52 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype | Total, No (n=13,205,1092) | 653 participants |
Comparison: G1p-value: 0.0081Cochran-Armitage Trend Test
Comparison: G2p-value: 0.0563Cochran-Armitage Trend Test
Comparison: G3p-value: 0.3516Cochran-Armitage Trend Test
Comparison: G4p-value: 0.0064Cochran-Armitage Trend Test
Comparison: Other genotypesp-value: 0.2707Cochran-Armitage Trend Test
Comparison: Total genotypesp-value: <0.0001Cochran-Armitage Trend Test
Secondary
Number of Participants With ITPA Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Experienced
Participants underwent blood sampling at the Study Visit to determine ITPA genotype.
Time frame: Study Visit 1
Population: Core Analysis Population (Treatment-Experienced).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Experienced | Experienced: ITPA rs1127354 CA | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Experienced | Experienced: ITPA rs1127354 AA | 0 participants |
| Naive: IL28B rs12979860 Cysteine-Cysteine (CC) | Number of Participants With ITPA Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Experienced | Experienced: ITPA rs1127354 CC | 18 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Experienced | Experienced: ITPA rs1127354 CA | 23 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Experienced | Experienced: ITPA rs1127354 AA | 0 participants |
| Naive: IL28B rs12979860 Threonine-Cysteine (TC) | Number of Participants With ITPA Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Experienced | Experienced: ITPA rs1127354 CC | 246 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Experienced | Experienced: ITPA rs1127354 AA | 15 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Experienced | Experienced: ITPA rs1127354 CC | 1185 participants |
| Naive: IL28B rs12979860 Threonine-Threonine (TT) | Number of Participants With ITPA Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Experienced | Experienced: ITPA rs1127354 CA | 211 participants |
p-value: 0.0066Chi-squared